seizure due multiple drug intoxication : case report . mechanism antidepressant effect bupropion fully understood . besides , using treatment depression , found effective reducing withdrawal symptom due smoking cessation . 28-year-old female patient history depression admitted emergency department hour ingestion bupropion , quetiapine , levothyroxine high dos commit suicide . accepting intensive care unit , awake , alert , disoriented agitated . 2h , patient generalized tonic-clonic seizure . necessary treatment given 9h later hemodynamic improvement , patient ' mental status improved . bupropion may cause unusual behavior delusion , paranoia , hallucination , confusion . risk seizure strongly dose-dependent . want emphasize importance early gastric lavage administration activated charcoal . bupripion bupropiona convulsão intensive care unit seizure unidade de terapia intensiva
efficacy ranitidine olanzapine-induced weight gain : dose-response study . weight gain long recognized side-effect atypical antipsychotic drug . numerous new approach tried prevention weight gain , h2 blocker one . study conducted aim evaluate efficacy ranitidine olanzapine-induced weight gain two fixed dos 150 300 mg day seventy-five inpatient icd-10-dcr diagnosis schizophrenia first episode randomized three group 25 patient , receiving 150 mg day patient comparable respect weight bmi baseline . change weight bmi assessed 4 8 week baseline , significant difference observed three group . ranitidine dos 150 300 mg day olanzapine ranitidine weight gain
characterization evaluation self-nanoemulsifying sustained-release pellet formulation ziprasidone enhanced bioavailability food effect . purpose work develop self-nanomulsifying drug delivery system ( snedds ) sustained-release pellet ziprasidone enhance oral bioavailability overcome food effect ziprasidone . preformulation study including screening excipients solubility pseudo-ternary phase diagram suggested suitability capmul mcm oil phase , labrasol surfactant , peg 400 co-surfactant preparation self-nanoemulsifying formulation . preliminary composition snedds formulation selected pseudo-ternary phase diagram . prepared ziprasidone-snedds formulation characterized self-emulsification time , effect ph robustness dilution , droplet size analysis zeta potential . optimized ziprasidone-snedds used prepare ziprasidone-snedds sustained-release pellet via extrusion-spheronization method . pellet characterized sem , particle size , droplet size distribution zeta potential . vitro drug release study indicated ziprsidone-snedds sustained-release pellet showed sustained release profile 90 % released within 10 h. ziprsidone-snedds sustained-release pellet administered fasted fed beagle dog pharmacokinetics compared commercial formulation zeldox control . pharmacokinetic study beagle dog showed ziprasidone prolonged action enhanced bioavailability food effect achieved simultaneously ziprsidone-snedds sustained-release pellet compared zeldox fed state . result indicated sustained release prolonged action schizophrenia bipolar disorder treatment . bioavailability enhancement food effect self-nanoemulsifying sustained release ziprasidone
pharmacokinetic profile multiple deltoid gluteal intramuscular injection paliperidone palmitate patient schizophrenia . paliperidone palmitate ( pp ) once-monthly long-acting injectable antipsychotic approved treatment schizophrenia many country . evaluate different injection-site option , compared pharmacokinetic profile paliperidone multiple injection pp 100 mg eq . ( 156 mg pp , equivalent 100 mg paliperidone ) day 1 , 8 , 36 , 64 deltoid ( n = 24 ) gluteal muscle ( n = 25 ) patient schizophrenia . four injection deltoid muscle , paliperidone exposure higher aucτ cmax , compared gluteal muscle ( geometric mean aucτ -based ratio : 120 % [ 90 % ci : 93.1-154.7 % ] , geometric mean cmax -based ratio : 130 % [ 90 % ci : 100.6-168.9 % ] ) . mean [ sd ] fluctuation index higher , larger interpatient variability , deltoid-injections ( 75.9 % [ 30.9 % ] ) gluteal-injections ( 58.5 % [ 14.3 % ] ) . median tmax similar site . pp generally tolerable patient , favorable local-site tolerability gluteal-injection . conclusion , achieve therapeutic-concentrations quickly , first-two injection pp best administered deltoid muscle , whereas thereafter maintenance-injections administered either deltoid gluteal muscle . atypical long-acting injectable deltoid gluteal muscle paliperidone palmitate pharmacokinetics schizophrenia
pregabalin treatment patient complex regional pain syndrome . complex regional pain syndrome ( crp ) painful disabling neurovascular condition . consensus etiopathogenesis treatment . present patient crp type 1 accompanied psychiatric disorder discus relationship crp psychiatric disease emphasize response case treatment pregabalin . 15-year-old girl presented swelling , severe pain , edema , hyperesthesia , allodynia , sweating change left arm diagnosed crp type 1 . presence disturbed family relation revealed psychiatric examination , diagnosis major depression made . symptom respond selective serotonin reuptake inhibitor noradrenergic specific serotonergic antidepressives , gabapentin , stellate ganglion blockage , patient 's pain resolved pregabalin . symptom-oriented measure psychiatric support enabled ongoing treatment . social service evaluation led placed care social service protect chaotic traumatic family life . detailed psycological psychiatric evaluation recommended individual crp psychiatric support improvement associated psychosocial concern addition pregabalin seems facilitate treatment patient . complex regional pain syndrome depression pain pregabalin
rare case acute clozapine- related thrombogenic myocarditis . none
latent bipolarity unipolar depression : experimental finding , conceptual analysis implication treatment strategy . previous study suggested two opposite pole psychomotor disturbance unipolar depression ( ud ) - retardation agitation - require different treatment strategy psychomotor overactivation requires augmentation antidepressant therapy mood stabilizer and/or atypical antipsychotic . aim present study objectively identify measure psycho-motor disturbance ud using differentiation activity reactivity . equilibriometric movement pattern analysis system allows differentiation psychomotor activity reactivity applied 58 unipolar depressive patient 76 healthy control . compared control , patient group significantly slower psychomotor reactivity . however , subsequent subgrouping according direction deviation objective psychomotor parameter revealed disinhibition psychomotor activity and/or reactivity one half . contradictory combination clinically manifested depressive mood subclinically detected manic-like psychomotor overactivation might regarded belonging bipolar spectrum , since admitted manic psychomotor disinhibition unipolar depressive patient uncovers latent bipolarity . prototypical depressive inhibition , also prototypical manic-like disinhibition may underlie clinically manifested ud . since combination depressive mood psychomotor overactivation multiplies suicidal risk , may presume timely detection combination subclinical level would contribute earlier effective suicidal prevention objectively-guided optimization pharmacological treatment .
depressive disorder indian context : review clinical update physician . depression common , treatable disorder continues remain under-detected primary care setting . average national deficit 77 % psychiatrist india , need mobilise resource deal depressive disorder . therefore , pertinent physician sensitised trained recognition treatment depressive disorder . patient mild moderate depression , non-psychotic somatised depression managed primary care setting general physician . unless specifically screened , depression may remain under-recognised untreated primary care/medical setting . article review available indian research depression provide clinical update screen , diagnose manage depression , especially aimed physician .
magnetic resonance imaging measure brain structure predict antidepressant treatment outcome major depressive disorder . le 50 % patient major depressive disorder ( mdd ) reach symptomatic remission initial antidepressant medication ( adm ) . currently objective measure reliably predict individual achieve remission adms . 157 participant mdd international study predict optimized treatment depression ( ispot-d ) underwent baseline mri completed eight week treatment escitalopram , sertraline venlafaxine-er . score week 8 7 le 17 item hamilton rating scale depression defined remission . receiver operator characteristic ( roc ) analysis using first 50 % participant performed define decision tree baseline mri volumetric connectivity ( fractional anisotropy ) measure differentiated non-remitters remitters maximal sensitivity specificity . decision tree tested replication remaining participant . overall , 35 % participant achieved remission . roc analysis identified two decision tree predicted high probability non-remission replicated : 1 . left middle frontal volume < 14 · 8 ml & right angular gyrus volume > 6 · 3 ml identified 55 % non-remitters 85 % accuracy ; 2 . fractional anisotropy value left cingulum bundle < 0 · 63 , right superior fronto-occipital fasciculus < 0 · 54 right superior longitudinal fasciculus < 0 · 50 identified 15 % non-remitters 84 % accuracy . participant met criterion decision tree correctly identified non-remitters . pretreatment mri measure seem reliably identify subset patient remit first step medication includes one commonly used medication . finding consistent neuroanatomical basis non-remission depressed patient . brain resource ltd sponsor ispot-d study ( nct00693849 ) . biomarker predictor decision tree diffusion tensor imaging magnetic resonance imaging major depressive disorder remission replication ispot-d
predict treatment outcome depression ? none
[ influence reamberin® cycloferon® concetration `` average molecule '' serum patient reccurent depressive disorder outpatient observation ] . influence reamberin® cycloferon® concentration `` average molecule '' serum patient recurrent depressive disorder ( rdd ) investigated . set use drug help normalize concentration `` average molecule '' . indicates elimination syndrome `` metabolic '' intoxication . based data , consider appropriate inclusion reamberin® cycloferon® therapeutic treatment patient rdr .
trend use antidepressant among older adult : bambuí project . objective analyze trend factor associated antidepressant use among older adult . method population-based study evaluated older adult 1997 ( n = 351 , baseline ) survivor 15th follow-up year ( n = 462 , 2012 ) among aging cohort bambuí . prevalence antidepressant use estimated , commonly used antidepressant year identified . prevalence ratio 95 % confidence interval estimated using poisson regression robust variance investigate difference prevalence use 1997 2012 . result overall consumption antidepressant ( pr = 2.87 , 95 % ci 1.94 ; 4.25 ) selective serotonin reuptake inhibitor ( pr = 7.50 , 95 % ci 3.74 ; 15.02 ) significantly higher 2012 . however , significant difference observed use tricyclic antidepressant two cohort ( pr = 0.89 , 95 % ci 0.49 ; 1.62 ) . 2012 cohort , antidepressant use associated female , increased age , increased income ( ≥ 4 minimum wage ) , self-assessment health reasonable , attending ≥ 5 medical consultation last 12 month . conclusion increased consumption antidepressant period due increased use selective serotonin reuptake inhibitor consistent result observed international study different population group context . positive correlation observed antidepressant use family income may warning possible inequality access mental health service . analisar tendência e o fatores associados ao uso de antidepressivos por idosos mais velhos . estudo de base populacional com idosos integrantes da linha base ( n = 351 , em 1997 ) e do sobreviventes 15º seguimento ( n = 462 , em 2012 ) da coorte idosa de bambuí . estimou-se prevalência consumo de antidepressivos e foram identificados o antidepressivos mais consumidos em cada ano . razões de prevalência com intervalos de confiança de 95 % foram estimadas por meio da regressão de poisson , com variância robusta , na investigação de diferenças de prevalência uso medicamento entre o doi ano . consumo global de antidepressivo ( rp = 2,87 ; ic95 % 1,94 ; 4,25 ) e grupo do inibidores seletivos da recaptura da serotonina ( rp = 7,50 ; ic95 % 3,74 ; 15,02 ) foi significativamente maior em 2012 . entretanto , não foi observada diferença significativa consumo de antidepressivos tricíclicos entre duas coortes ( rp = 0,89 ; ic95 % 0,49 ; 1,62 ) . na coorte recente ( 2012 ) , uso de antidepressivos mostrou-se associado ao sexo feminino , à idade e à renda ( ≥ 4 salários mínimos ) mais elevadas , à autoavaliação da saúde como razoável e à realização de cinco ou mais consultas médicas no últimos 12 me . crescimento consumo de antidepressivos período , devido ao aumento uso do inibidores seletivos da recaptura da serotonina , mostrou-se consistente com observado em estudos internacionais , com diferentes populações e contextos . associação positiva observada em relação à renda alerta para possível desigualdade acesso aos serviços de saúde mental .
neuroleptic malignant syndrome probably induced asenapine . none
aripiprazole monotherapy relieve rumination case nonpsychotic depression . none
hyponatremia masquerading panic symptom bipolar affective disorder . none
fluoxetine-induced pulmonary hypertension patient schizophrenia . none
pharmacological management persistent hostility aggression person schizophrenia spectrum disorder : systematic review . incidence aggressive behavior higher among person schizophrenia spectrum disorder ( ssds ) among person without disorder . phenomenon represents risk well-being patient , family , society . author undertook systematic review english language literature determine efficacy neuropharmacological agent management hostility aggression among person ssds . search combined finding medline , embase , psycinfo database . ninety-two full text article identified reported relevant finding . american academy neurology criterion used determine level evidence . paliperidone-extended release probably effective management hostility among inpatient ssds preselected aggression ( level b ) . clozapine possibly effective haloperidol management overt aggression possibly effective chlorpromazine management hostility among inpatient ssds preselected aggression ( level c ) . clozapine also possibly effective olanzapine haloperidol reducing aggression among selected physically assaultive inpatient ( level c ) . adjunctive propranolol , valproic acid , famotidine possibly effective reducing aspect hostility aggression among inpatient ssds ( level c ) . paliperidone-extended release currently appears agent management hostility among inpatient ssds strongest evidence efficacy .
psychopharmacological potential methanol leaf extract securinega virosa roxb ( ex willd ) baill . mouse . schizophrenia highly disabling chronic psychiatric illness . existing antipsychotic agent associated untoward effect drug interaction leading intensification search newer agent better efficacy safety profile . securinega virosa commonly used medicinal plant african traditional medicine . decoction leaf plant combination plant used management mental illness . study , evaluate antipsychotic potential methanol leaf extract ( 25 , 50 100 mg kg ( -1 ) ) plant using apomorphine-induced stereotypic climbing behavior swim-induced grooming test , mouse . cns depressant effect also evaluated using ketamine-induced sleep test mouse . extract highest dose tested ( 100 mg kg ( -1 ) ) significantly reduced apomorphine ( 1 mg kg ( -1 ) ) -induced stereotypic climbing behavior 30 min . similarly , haloperidol ( 2 mg kg ( -1 ) ) , standard agent significantly ( p < 0.001 ) decreased mean climbing behavior . swim-induced grooming test , extract significantly ( p < 0.01 ) dose-dependently decreased total grooming time . similarly , haloperidol ( 2 mg kg ( -1 ) ) significantly ( p < 0.001 ) decreased mean grooming activity . extract significantly increased total ketamine-induced sleep duration dos 50 100 mg kg ( -1 ) . finding suggest extract posse antipsychotic sedative potential lend credence ethnomedical use leaf plant management mental illness .
psychopharmacological treatment delirium : earlier treatment scheduled dosing improve outcome ? goal study examine dosing strategy timeliness antipsychotic medication initiation would affect delirium duration . retrospective paper electronic record review patient academic hospital diagnosed delirium . forty-two patient met inclusion criterion . quantitative qualitative data course delirium gathered , well important demographic medical variable . significant difference duration delirium scheduled prn group using survival analysis , although test marginally significant ( log rank test , p < 0.06 ) . received treatment within 24 hour recognition significantly shorter duration delirium compared began treatment 24 hour ( log rank test , p < 0.006 ) . data suggest early psychopharmacological treatment delirium reduce duration . future research need investigate prompt scheduled medication dosing strategy treatment delirium symptom .
sertraline-induced microscopic colitis . none
[ intranasal application thyrotropin-releasing hormone attenuates state-anxiety rat ] . experiment investigated influence thyrotropin-releasing hormone ( trh ) change behaviour white rat ( rattus norvegicus ) male ( n = 90 ) , induced light uncontrolled impact . two-week procedure handling male rat tested using elevated plus-maze determine basal level anxiety , locomotor investigative activity emotionality . month later investigated influence intranasal administration trh-solution ( 10 ( -10 ) ) volume 20 mkl anxiety-level increase , induced stress : short electric foot-shocks . four hour later animal tested elevated plus-maze . vehicle-treated animal detected increase anxiety emotionality level decrease locomotor investigative activity . contrast increase anxiety emotionality trh-treated rat . locomotor investigative activity , decreased trh-treated animal well inthe vehicle-treated . show specific influence level anxiety , n't affect component stress-induced behavioral change present result suggest trh potential anxiolitic .
venlafaxine inhibits apoptosis hippocampal neuron up-regulating brain-derived neurotrophic factor rat depression model . effect venlafaxine expression brain-derived neurotrophic factor ( bdnf ) rat hippocampal neuron studied , well inhibitory effect apoptosis hippocampal neuron . difference behavioral ability depression model group venlafaxine treatment group observed behavioral , sucrose-water open field test . rat hippocampal tissue sliced , stained observed bdnf distribution immunohistochemistry . apoptosis hippocampal neuron detected tunel . bdnf expression hippocampal tissue detected western blot . injury apoptosis hippocampal tissue observed electron microscopy . behavioral test showed venlafaxine effectively improved behavioral ability depressed rat . immunohistochemistry showed venlafaxine markedly increased bdnf expression rat hippocampus . tunel showed venlafaxine markedly inhibited apoptosis hippocampal neuron , also confirmed electron microscopic observation pathologic section . venlafaxine improved expression bdnf influencing pi3k/pkb/enos pathway repressed apoptosis hippocampal neuron .
[ effect stimulation blockade d2-dopaminergic receptor behavior gonadectomized male rat ] . present study aim perform comparative assessment stimulation blockade d2-dopaminergic receptor depression-like behavior male rat deficiency androgen hormone . two week surgery , gdx rat began 14 day treatment vehicle , low dose testosterone propionate ( 0.5 mg/kg , s.c. ) , quinpirole ( 0.1 mg/kg , i.p . ) , sulpiride ( 10.0 mg/kg , i.p . ) , quinpirole plus testosterone propionate sulpiride plus testosterone propionate . animal tested forced swimming test ( fst ) open field test ( oft ) . quinpirole administered alone combination low dose testosterone propionate resulted antidepressant-like effect gdx rat fst . repeated treatment quinpirole testosterone propionate profoundly increased antidepressant-like effect single substance exert per se . application neither quinpirole quinpirole plus testosterone propionate led change behavioral reaction gdx rat oft , except increased grooming behavior . contrary , sulpiride treatment failed alter depression-like behavior gdx rat fst . addition , sulpiride blocked antidepressant-like effect testosterone propionate gdx rat combination low dose testosterone propionate induced prodepressant-like effect gdx rat . co-administration sulpiride testosterone propionate single application increased frequency rearing grooming gdx rat oft . summary , result present study suggest stimulation d2-dopaminergic receptor result antidepressant-like effect androgen deficiency male rat , blockade d2-dopaminergic receptor resulted prodepressant-like effect .
evaluation role nmda receptor function antidepressant-like activity . new study citalopram fluoxetine forced swim test mouse . nmda/glutamate receptor involved mechanism antidepressant activity . present study designed investigate effect nmda receptor ligand ( agonist antagonist glutamate site ) antidepressant-like activity selective serotonin reuptake inhibitor ( ssri ) , citalopram fluoxetine , forced swim test mouse . antidepressant activity ( reduction immobility time ) citalopram fluoxetine antagonized n-methyl-d-aspartate acid enhanced cgp37849 ( antagonist nmda receptor ) . present literature data indicate antidepressant-like activity conventional antidepressant generally affected nmda receptor , although modulation different site complex . thus , support issue ability nmda receptor antagonist enhance antidepressant action human depression . cgp 37849 citalopram fluoxetine forced swim test nmda
antidepressant-like effect modafinil mouse : evidence involvement dopaminergic neurotransmission . modafinil wake-promoting agent provides wide range neurological effect . evidence produce antidepressant effect . study investigated antidepressant effect modafinil tail suspension ( tst ) mouse . different dos modafinil intraperitoneally ( ip ) administrated animal subjected tst and/or open field test ( oft ) . moreover , implication dopaminergic neurotransmission modafinil 's antidepressant effect studied . purpose , animal pretreated haloperidol ( non-selective dopamine receptor antagonist ) , sch23390 sulpiride ( dopamine d1 d2 receptor antagonist , respectively ) , assessed tst . possible effect sub-effective dose modafinil combination sub-therapeutic dos standard antidepressant also evaluated separate group . modafinil ( 75 mg/kg , ip ) produced antidepressant effect tst , compared control group , without alteration ambulation oft . pretreatment mouse haloperidol ( 0.2mg/kg , ip ) sulpride ( 50mg/kg , ip ) blocked anti-immobility effect modafinil ( 75 mg/kg , ip ) . also found administration sch23390 ( 0.05 mg/kg , sc ) could n't antagonize antidepressant effect modafinil . addition , sub-effective dose modafinil ( 50mg/kg , ip ) potentiated sub-effective dos standard antidepressant including bupropion ( 1mg/kg , ip ) , fluoxetine ( 1mg/kg , ip ) imipramine ( 0.1mg/kg , ip ) reduced immobility time tst . result show modafinil induced antidepressant property tst effect apparently mediated interaction dopaminergic ( d2 receptor ) system . ( 2 ) dopamine receptor depression mouse modafinil tail suspension test
[ production assessing release imipramine magnesium tablet ] . pharmaceutical technology trend produce tablet composed several medicinal substance increase therapeutic effect reduce frequency drug administration . literature report concerning pharmacological study potentiation effect observed co-administration antidepressant imipramine magnesium . currently , formulation market comprising imipramine magnesium , therefore , decided produce uncoated tablet . order prepare tablet direct compression , necessary select suitable excipients . aim study elaborate composition prepare tablet imipramine magnesium , well ass quality tablet physical characteristic release study active substance . order prepare tablet , composition different polymer excipients added . tablet produced direct compression method tablet press . physical property obtained tablet release active substance acidic medium paddle apparatus tested . content imipramine magnesium determined different method : spectrophotometrically atomic absorption spectrometry , respectively . composition excipients necessary produce tablet comprising imipramine magnesium established . prepared tablet compliance pharmacopoeial requirement . release test showed 80 % imipramine released within 20-35 min 80-76 % magnesium 45 min composed tablet one-ingredient tablet , respectively . composition excipients tablet consisting imipramine magnesium presented . active substance released within 45 min acidic medium , administration substance composed tablet affect pharmaceutical availability .
antidepressant self-discontinuation : result collaborative psychiatric epidemiology survey . goal study examine extent correlate self-discontinuation antidepressant medication without physician advice . among 1,411 participant nationally representative collaborative psychiatric epidemiology survey reported using antidepressant past year , sociodemographic clinical correlate self-discontinuation medication without physician advice approval examined , along participant ' reason discontinuation . total 313 ( 22 % ) antidepressant user preceding year reported discontinuing antidepressant medication without physician advice approval . older individual reduced odds self-discontinuing antidepressant . participant anxiety substance use disorder prescribed antidepressant provider psychiatrist higher odds self-discontinuation . participant public insurance lower odds self-discontinuation private insurance . two commonly reported reason self-discontinuation antidepressant side effect experiencing benefit medication . physician prescribing antidepressant need clearly communicate expected benefit treatment , minimum duration use required experience benefit , potential side effect medication , particularly younger patient , anxiety disorder , patient treated general medical setting , increased odds self-discontinuation .
on-off effect dopaminergic therapy psychiatric symptom parkinson 's disease . psychiatric manifestation parkinson 's disease ( pd ) cause significant disability impact dopaminergic medication unclear . using standardized rating scale , author tested hypothesis anxiety , depression , apathy vary versus state pd 33 pd patient 29 healthy age- education-matched control . pd patient significantly higher anxiety , depression , apathy score control participant , regardless on-off state . anxiety score higher pd patient relative dopaminergic medication . on-off difference anxiety related degree improvement motor function illness duration .
author 's response . none
effect dietary tryptophan affective disorder . using randomized crossover study design , 25 healthy young adult examined difference anxiety , depression , mood consuming high tryptophan low tryptophan diet 4days . 2week washout diet . within-subjects analysis participant ' mood indicated significantly ( p < .01 ) positive affect score consuming high tryptophan diet compared low tryptophan diet . negative affect difference diet statistically significant ( p > .05 ) . also , consuming dietary tryptophan resulted ( p < .05 ) le depressive symptom decreased anxiety .
[ glutamate receptor gene polymorphism risk paranoid schizophrenia russian tatar republic bashkortostan ] . schizophrenia severe mental disorder affect 1 % world population , leading disability social exclusion . glutamatergic neurotransmission violation one main hypothesis put forward explain neurobiological mechanism schizophrenia . post mortem study found change degree affinity glutamate receptor , transcription , altered expression subunit prefrontal cortex , hippocampus , thalamus patient schizophrenia . result genetic study gene family encoding ionotropic ampa kainate glutamate receptor schizophrenia , ambiguous result received . association polymorphic variant gene gria2 grik2 paranoid schizophrenia response therapy haloperidol russian tatar republic bashkortostan conducted present study . dna sample 257 patient paranoid schizophrenia 349 healthy control russian tatar ethnic group living republic bashkortostan involved present study . result present study : ( 1 ) high risk genetic marker paranoid schizophrenia ( psz ) obtained : russians-gr4ia2 * ccc ( = 9.60 ) tatars-grik2 * atg ( = 3.5 ) , grik2 * tgg ( = 3.12 ) ( 2 ) following low risk genetic marker psz revealed : tatars-gria2 * t/t ( rs43025506 ) gria2 gene ( = 0.34 ) ; russians.- gria2 * cct ( = 0.481 ) . ( 3 ) genetic marker low haloperido ! treatment efficacy respect negative positive symptom grik2 * t/t ( rs2227281 ) grik2 gene gral42 * c/c russian , grik2 * a/a ( rs995640 ) grik2 gene tatar . ( 4 ) genetic marker low haloperidol treatment efficacy respect positive symptom grl42 * c/c russian . result present study support hypothesis involvement glutamate receptor gene schizophrenia pathway . considerable inter-ethnic'diversity genetic risk factor disease revealed .
le -- possible option treatment depression . depression illness modern society , affect population different age . etiological factor differ , frustration factor cause depression multiplying . new episode present difficulty , patient psychiatrist . despite increasing number antidepressant use treatment , sometimes hard notice efficient antidepressant optimal-efficient dose . resistant case apply combination psychopharmacs , choice depends leading symptom . present case 67-year-old patient depressive episode ( term reccurent major depressive disorder ) last one year . period treated outpatient inpatient several antidepresants combination psychopharmacotherapeutical drug . despite regular treatment , mental state worsening . clinical presentation indicating developing dementia ( behavior , cognition outges ) , excluded diagnostic process . psychopharmacological combination ( antidepresants , mood stabilizators , antypschotics , anxsiolotix ) efficant . progression simptoms lead rehospitalisation . treatmen , followed principle `` le '' resulted expected satisfactory outcome .
detection treatment mental health issue pediatric pcp new york state : evaluation project teach . author evaluated project teach ( pt ) , statewide training consultation program pediatric primary care provider ( pcp ) identification treatment mental health condition . intervention group 176 pcp volunteered pt training compared stratified random sample 200 pcp receive pt training . data prescription practice , diagnosis , follow-up care new york state medicaid file ( 2009-2013 ) youth seen trained ( n=21,784 ) untrained ( n=46,607 ) pcp . percentage child prescribed psychotropic medication increased pt training ( 9 % 12 % , p < .001 ) , larger increase untrained group ( 4 % 5 % , p < .001 ) ( comparison , p < .001 ) . fewer difference noted diagnosis medication use follow-up care among child depression . intervention may impact provider ' behavior , research needed clarify effectiveness .
first outpatient follow-up psychiatric hospitalization : one size fit ? claims-based indicator follow-up within seven 30 day psychiatric discharge face validity quality measure : early follow-up may improve disease management guide appropriate service use . yet indicator rarely examined empirically . study assessed association subsequent health care utilization adult comorbid condition . postdischarge follow-up subsequent utilization examined among adult enrolled north carolina medicaid discharged claims-based diagnosis depression schizophrenia readmitted within 30 day . total 24,934 discharge ( 18,341 individual ) fiscal year 2008-2010 analyzed . follow-up categorized occurring within 0-7 day , 8-30 day , none 30 day . outcome subsequent six month included psychotropic medication claim , adherence ( proportion day covered ) , number hospital admission , emergency department visit , outpatient visit . follow-up within seven day associated greater medication adherence outpatient utilization , compared follow-up 30 day . observed follow-up mental health provider provider . adult receiving mental health follow-up within seven day equivalent , lower , subsequent inpatient emergency department utilization without follow-up within 30 day . however , adult receiving follow-up provider within seven day likely follow-up inpatient admission emergency department visit subsequent six month . difference subsequent utilization observed mental health follow-up within seven day versus eight 30 day . patient readmitted within 30 day , follow-up within 30 day appeared beneficial basis subsequent service utilization .
tricyclic ssri usage influence association bmi health risk factor . determine selective-serotonin reuptake inhibitor ( ssri ) tricyclic antidepressant ( tcas ) influence association obesity cardiovascular disease risk , participant third national health nutrition examination survey ( nhanes iii ; 1988-1992 ) continuous nhanes ( 1999-2009 , n = 18 274 ) used . given body mass index ( bmi ) , individual taking ssri ( n = 219 ) tended significantly better health risk profile lower systolic blood pressure ( p = 0.002 ) higher high-density lipoprotein ( p = 0.003 ) compared non-users . conversely , used tcas ( n = 116 ) significantly worse health risk profile higher diastolic blood pressure ( p ≤ 0.0001 ) triglyceride ( p = 0.023 ) compared non-users given bmi . insulin resistance ( homa-ir ) higher tca user larger bmi , whereby difference insulin resistance tca user non-users greater higher bmi ( interaction effect : p = 0.013 ) . furthermore , individual taking ssri le likely cardiovascular disease non-users ( odds ratio , 95 % confidence interval = 0.50 , 0.33-0.75 ) given bmi , difference tca use ( odds ratio = 0.74 , 0.44-1.24 ) . ssri tca use may alter body weight relates cardiovascular risk . prescribing antidepressant medication , may necessary monitor consider body weight cardiovascular risk profile individual patient . antidepressant bmi cardiovascular disease health risk
prolonged mania case bipolar affective disorder . bipolar disorder , often onset adolescence early adulthood , characterised marked variation mood , ranging major depressive episode manic exacerbation . compared depressive episode , manic recurrence often brief usually respond anti-manic medication within week . infrequently bipolar patient get badly affected protracted manic symptom exhibit resistance usual anti-manic agent . mania disruptive condition severe adverse consequence patient , every effort made bring control soon possible . nonetheless , occasional patient may require prolonged persistent treatment attain remission . case manic symptom showing resistance , evidence-based pharmacotherapuetic approach treating physician essential . provision psychological social support patient vital conjunction biological measure optimal management .
refinement swn-20 based rasch rating model . aim present study refine 20-item subjective well-being neuroleptic treatment scale ( swn-20 ) using rasch rating model validate measurement subjective well-being patient schizophrenia undergoing antipsychotic treatment . total , 854 ( 403 male , 451 female ) inpatient ( n=213 ) outpatient ( n=641 ) schizophrenia participated study , designed open-label investigation paliperidone extended release . participant completed korean version swn-20 . refinement korean version swn-20 accomplished using rasch rating model . infit outfit statistic 20 item satisfied criterion construct validity . second , item except item 2 20 suitable point-measure correlation , reflecting content validity . third , item characteristic curve indicated roughly 18 item evenly distributed along person ability continuum . finally , option analysis category characteristic showed category 3 4 swn-20 response format unnecessary . offer several recommendation improving swn-20 : ( ) item 2 20 omitted ensure construct validity ; ( b ) easier item would added related person ability estimate process validating short form swn scale based item response theory ; ( c ) number response category reduced schizophrenic patient .
comparison white hispanic woman 's story adjustment birth child . part larger project designed inform prevention treatment postpartum depression promote positive mother-child relationship diverse family , study describes personal story postnatal adjustment 14 white 9 hispanic woman recruited prenatal care clinic . qualitative interview conducted mother ' primary language ( english spanish ) analyzed using modified grounded theory content-analysis approach . coding scheme developed capture woman 's discourse experience included child temperament health ; intergenerational pattern ; work demand job loss ; schedule change ; increased responsibility ; difficulty parenting task ; emotional distress ; social stressor resource ; coping strategy ; change work , personal , social , marital domain . white mother hispanic mother reported change time structure , work stressor , use psychotropic medication , informational support , social support mother professional ; however , within-group difference evident cross-group ethnic difference . analysis qualitative interview led integration belsky 's determinant parenting model ( 1984 ) double abcx model family adjustment adaptation ( mccubbin & patterson , 1983 ) hybrid third theoretical framework .
multiple sclerosis : role melatonin n-acetylserotonin . multiple sclerosis ( m ) immune mediated disorder intensive investigation attempt improve available treatment . many change occurring m , including increased mitochondrial dysfunction , pain reporting depression may partly mediated increased indoleamine 2,3-dioxygenase , drive tryptophan production neuroregulatory tryptophan catabolites away serotonin , n-acetylserotonin melatonin production . consequence decreased melatonin classically attributed circadian change following release pineal gland . however , recent data show melatonin may produced mitochondrion containing cell degree , including astrocyte immune cell , thereby providing another important m treatment target . well powerful antioxidant , anti-inflammatory antinociceptive , melatonin improves mitochondrial functioning , partly via increased oxidative phosphorylation . melatonin also inhibits demyelination increase remyelination , suggesting local regulation white matter astrocyte serotonin availability apolipoprotein e4 , among potential factor , important etiology , course treatment m . review role local melatonin precursor , n-acetylserotonin serotonin , ms. depression melatonin mitochondrion multiple sclerosis n-acetylserotonin remyelination
[ bi value useful evaluation consciousness recovery acute vegetamin-a poisoning : report case ] . 37-year-old man admitted hospital acute phenobarbital poisoning . arrival , deep coma respiro-circulatory depression . serum concentration agent elevated 149.04 μg/ml consistent lethal concentration level . underwent gastric lavage , administration activated charcoal , urinary alkalinazation bowel irrigation . respiro-circulatory status recovered rapidly , serum concentration phenobarbital decrease smoothly . although concentration agent decreased 77.07 μg/ml comatose level , bi value gradually elevated , eventually patient regained consciousness . chronic user vegetamin-a containing phenobarbital , serum level might correlated symptom . bi value highly reflective consciousness level , could useful indicator predicting consciousness level patient deep coma acute poisoning hypnotic agent .
avoiding contamination randomized controlled trial . none
social inequality antidepressant use canada france : reply . none
social inequality antidepressant use canada france . none
response parikh . none
brief versus intensive psychosocial treatment bipolar disorder : time stepped care ? none
pulmonary embolism psychiatric patient . none
matric consensus cognitive battery : know 6 year later . none
pharmacogenetics outcome antipsychotic drug . antipsychotic medication gold-standard treatment schizophrenia , often prescribed mental condition . however , efficacy side-effect profile drug heterogeneous , large interindividual variability . result , treatment selection remains largely trial-and-error process , many failed treatment regimen endured finding tolerable balance symptom management side effect . much interindividual variability response side effect due genetic factor ( heritability , h ( 2 ) ~ 0.60-0.80 ) . pharmacogenetics emerging field hold potential facilitate selection best medication particular patient , based genetic information . review discus promising genetic marker antipsychotic treatment outcome , present current translational research effort aim bring pharmacogenetic finding clinic near future . los antípsicóticos son los medícamentos utilizados como gold standard para el tratamiento de la esquizofrenía además se emplean con frecuencia para otros trastornos mentales . sin embargo , los perfiles de eficacia efectos secundarios de estos fármacos son heterogéneos con gran varíabílidad ínterindividual . raíz de esto , la selección del tratamiento sígue siendo un largo proceso de ensayo-error , con muchas falla terapéuticas que se deben soportar ante de encontrar un balance aceptable entre el manejo sintomático los efectos secundarios . mucha de la varíabílidad ínterindividual en la respuesta los efectos secundarios se debe factores genéticos ( heredabilidad , h le médicaments antipsychotiques , traitement de référence pour la schizophrénie , sont souvent prescrits pour d'autres malady mentales . néanmoins , leur efficacité et leurs effets indésirables sont hétérogenes , avec une grande variabilité selon le individus . en conséquence , le choix du traitement procède en grande partie par tâtonnements , beaucoup de schémas thérapeutiques échouant avant que soit trouvé un rapport correct entre le effets sur le symptômes et le effets indésirables . de facteurs génétiques sont responsables de la majeure partie de la variabilité interindividuelle dans le réponses au traitement et le effets indésirables ( héritabilité , h antipsychotic genetic personalized medicine pharmacogenetics response schizophrenia side effect
prediction individual response antidepressant antipsychotic : integrated concept . clinical trial daily practice , substantial inter- even intraindividual variability response -- whether beneficial adverse -- antidepressant antipsychotic medication . far , tool become available predict outcome treatment specific patient . cause variability often known , , way predicting effect various potential combination individual . given background , paper present conceptual framework understanding known factor combination eventually clinician better predict medication ( ) select dose optimize outcome given individual . framework flexible enough readily adaptable new information becomes available . cause variation patient response grouped four category : ( ) genetics ; ( ii ) age ; ( iii ) disease ; ( iv ) environment ( internal ) . four case increasing complexity used illustrate applicability framework clinically relevant way addition , paper review tool clinician use ass quantify inter- intraindividual variability . information gained , treatment adjusted compensate variability , order optimize outcome . finally , limitation existing antidepressant antipsychotic therapy way reduce current ability predict response discussed . tanto en los ensayos clínicos como en la práctica diaria puede existir una importante variablidad inter e incluso intraindividual en la respuesta los efectos favorables adversos de medicación antidepresiva antipsicótica . hasta ahora se dispone de herramientas que puedan predecir el resultado de estos tratamientos en pacientes espetíficos . esto e porque la causa de tal variabilidad menudo son desconotidas , cuando se conocen , hay forma de predecir los efectos de sus varias combinaclones posibles para un sujeto . teniendo en cuenta estos antecedentes , esta revisión presenta un marco conceptual para la comprensión de los factores conocidos sus combinaciones para que los clínicos , eventualmente , puedan predecir mejor qué fármaco ( ) selectionar en qué dosis , para optimizar el resultado para un sujeto determinado . este marco e bastante flexible para ser fácilmente adaptable en la medida que se disponga de nueva información . la causa de la variación en la respuesta del paciente se agrupan en cuatro categoríes : ) genetica , b ) edad , c ) enfermedad ) ambiente ( interno ) . se emplean cuatro casos de complejidad creciente para ilustrar la aplicabilidad de este marco de una manera clínicamente relevante . además este artículo revisa herramientas que el clínico puede emplear para evaluar cuantificar variabilidad inter e intraindividual . con la información obtenida el tratamiento puede ser ajustado para compensar tal variabilidad , con el fin de optimizar el resultado . por último , se discuten la limitaciones de la terapia antidepresiva antipsicótica existentes la manera de reducir la posibilidades actuales de predicción de la respuesta . que ce soit dans le études cliniques ou la pratique quotidienne , la variabilité de réponses inter- et même intra-individuelles ( bénéfiques ou indésirables ) aux traitements antidépresseurs et antipsychotiques peut être importante . jusqu ' présent , nous ne disposons d'aucun outil pour prévoir le résultats de ce traitements chez de patient donnés , parce que le cause d'une telle variabilité sont souvent inconnues et quand elles le sont , il n ' pa de moyen de prévoir le effets de leurs association possible chez une personne . dans ce contexte , cet article présente un cadre conceptuel pour comprendre le facteurs connus et leurs association afin que le médecins puissent finalement mieux prévoir quel ( ) médicament ( ) choisir et à quelle dose pour obtenir le meilleurs résultats chez une personne en particulier . ce cadre est suffisamment flexible pour s'adapter facilement dès que de nouvelles données sont disponibles . le cause de variation de la réponse de patient sont regroupées en quatre catégories : 1 ) génétique ; 2 ) âge ; 3 ) maladie ; 4 ) environnement ( interne ) . quatre ca de difficulté croissante illustrent la mise en pratique de ce cadre d'une façon cliniquement pertinente . de plus , cet article examine le outils que le médecin peut utiliser pour évaluer et quantifier la variabilité inter et intra-individuelle . avec ce information , le traitement peut être ajusté pour compenser une telle variabilité et optimiser le résultat . enfin nous analysons le limites de traitements antidépresseurs et antipsychotiques existants et en quoi cela diminue la possibilité de prédire la réponse thérapeutique .. age antidepressant antipsychotic disease drug-drug interaction genetics multiple medication use polypharmacy regulatory protein
using biomarkers predict treatment response major depressive disorder : evidence past present study . major depressive disorder ( mdd ) heterogeneous condition variable response wide range treatment . despite intensive effort , biomarker identified date reliably predict response non-response form treatment , one identified used identify high risk developing treatment-resistant depression ( ie , non-response sequence treatment delivered adequate duration intensity ) . manuscript review past area research proved informative , study using index hypercortisolism sleep disturbance , recent research finding using measure inflammation different indicator regional cortical activation predict treatment response . concluded , although method yet demonstrated sufficiently accurate applied clinical practice , progress made . thus seems likely -- point not-too-distant future -- possible prospectively identify , least mdd patient , likelihood response non-response cognitive therapy various antidepressant medication . el trastorno depresivo mayor ( tdm ) e una condíción heterogenéa con una respuesta variable una diversidad de tratamientos . pesar de grandes esfuerzos , la fecha se ha identificado ningún biomarcador confiable que pueda predecir la respuesta falta de ella para alguna forma de tratamiento , ni se ha encontrado alguno que pueda ser empleado para identificar los pacientes con alto riesgo de desarrollar una depresión resistente al tratamiento ( por ejemplo , falta de respuesta una secuencia de tratamientos aplicados con una duración e intensidad adecuadas ) . este artículo revisa algunas investigaciones antigua que aportaron información , como los estudios que emplearon indicadores de hipercortisolismo alteraciones del sueño , hallazgos de investigaciones más recientes que han empleado marcadores de la inflamación diferentes indicadores de activación cortical regional para predecir la respuesta terapéutica . se concluye que , aunque se han realizado progresos , aun se ha demostrado que algún método sea totalmente preciso para ser aplicado en la práctica clínica . parece ser entonces que , en algún momento del futuro cercano , será posible identificar prospectivamente -al menos para algunos pacientes con tdm- la probabilidad de respuesta falta de ella la terapia cognitiva varios farmacos antidepresivos . le trouble dépressif majeur ( tdm ) est une pathologie hétérogène dont la réponse à une large gamme de traitement est variable . malgré de effort considérables , à ce jour , aucun biomarqueur n ' été identifié pour prédire de façon fiable une réponse ou une non-réponse à un traitement donné , ou pour identifier le patient à risque élevé de développer une dépression résistante au traitement ( c'est-a-dire l'absence de réponse après une série de traitements administrés avec une dose et une durée adéquates ) . cet article passe en revue d'anciens domaines de recherche intéressants tels que le études sur le marqueurs d'un hypercortisolisme ou sur de anomaly du sommeil , ainsi que de résultats de travaux récents sur la mesure de l'inflammation et sur de indicateurs d'activation corticale régionale pour prédire la réponse au traitement . en conclusion , bien qu'aucun examen biologique précis n'ait été encore validé pour être utilisé en pratique clinique , de progrès ont été faits . il est donc probable que , dans un futur pa trop éloigné , il serum possible d'identifier de façon prospective , au moins pour certains patient atteints de tdm , la probabilité de réponse ou de non-réponse à un traitement cognitif ou aux différents antidépresseurs . antidepressant biomarker cognitive behavior therapy prediction treatment response
intermediate phenotype biomarkers treatment outcome major depressive disorder . major depressive disorder ( mdd ) pleomorphic illness originating gene x environment interaction . patient differing symptom phenotype receive diagnosis similar treatment recommendation without regard genomics , brain structure function , physiologic psychosocial factor . using present approach , one third patient enter remission first medication prescribed , patient may take longer 1 year enter remission repeated trial . research improve treatment effectiveness recently focused identification intermediate phenotype ( ip ) could parse heterogeneous population patient mdd subgroup homogeneous response treatment . ip could used develop biomarkers could applied clinically match patient treatment would likely lead remission . putative biomarkers include genetic polymorphism , rna protein expression ( transcriptome proteome ) , neurotransmitter level ( metabolome ) , additional measure signaling cascade , oscillatory synchrony , neuronal circuit neural pathway ( connectome ) , along possible physiologic measure . measure represent component continuum extends proximity genome proximity clinical phenotype depression , many level along continuum useful ip may defined . highly integrative nature brain system complex neurobiology depression , useful biomarkers likely intermediate proximity genome clinical phenotype mdd . translation finding across spectrum genotype phenotype promise better characterize complex disruption signaling neuroplasticity accompany mdd , ultimately lead greater understanding cause depressive illness . el trastorno depresivo mayor ( tdm ) e una enfermedad de variadas formas que surge partir de la interacciones entre gene ambiente ( gxa ) . los pacientes con fenotipos de diferentes síntomas reciben el mismo diagnóstico similares recomendaciones terapéuticas sin tener en consideración la genómica , la estructura función cerebral , u otros factores fisiológicos psicosociales . de acuerdo con esta aproximación solo un tercio de los pacientes alcanza la remisión con la primera medicación prescrita , los pacientes pueden tardar más de un año en alcanzar la remisión con diversos ensayos . recientemente la investigación para mejorar la eficacia terapéutica se ha enfocado en la identificación de fenotipos intermedios ( fis ) que podrían ser útiles para analizar la heterogénea población de pacientes con tdm en subgrupos con respuestas más homogéneas al tratamiento . estos fis podrían emplearse para desarrollar biomarcadores con aplicación en la clínica para indicar el tratamiento que tenga más probabilidades de alcanzar la remisión . estos llamados marcadores incluyen polimorfismos genéticos , expresión de arn proteínas ( transcriptoma proteoma ) , niveles de neurotransmisores ( metaboloma ) , mediciones adicionales de cascadas de señales , sincronía oscilatoria , circuitos neuronales vías neurales ( conectoma ) junto con otras posibles mediciones fisiológicas . toda estas mediciones representan componentes de un continuo que va desde la proximidad al genoma hasta la proximidad al fenotipo clínico de la depresión hay muchos niveles lo largo de este continuo en los cuales se pueden definir fis útiles . dada la naturaleza altamente integradora de los sistemas cerebrales la compleja neurobiología de la depresión , los biomarcadores ma útiles son probablemente aquellos que tienen una proximidad intermedia tanto con el genoma como con el fenotipo clínico del tdm . la traslación de los hallazgos través del espectro desde el genotipo al fenotipo promete caracterizar mejor la complejas disrupciones en la señales en la neuroplasticidad que acompañan al tdm finalmente conducir una mayor comprensión de la causa de la enfermedad depresiva . le trouble dépressif majeur ( tdm ) est une maladie pléomorphe due à de interaction entre le gènes et l'environnement ( g x e ) . le patient ayant de symptômes phénotypiques différents sont diagnostiqués et traités de la même façon , sans tenir compte de la génomique , de la fonction ou de la structure cérébrales ou d'autres facteurs physiologiques ou psychosociaux . suivant cette stratégie , seulement un tier de patient entrent en rémission avec le premier médicament prescrit et , après de traitements multiple , cette rémission met plus ' 1 à survenir . afin d'améliorer l'efficacité thérapeutique , le chercheurs se sont récemment intéressés à l'identification de phénotypes intermédiaires ( pi ) permettant d'analyser la population hétérogène de patient atteints de tdm en sous-groupes plus homogènes en termes de réponse au traitement . de tels pi pourraient être utilisés dans le développement de biomarqueurs afin d'apparier le patient au traitement le plus à même d'induire une rémission . le polymorphismes génétiques , l'expression de protéines et de l'arn ( transcriptome et protéome ) , le taux de neurotransmetteurs ( métabolome ) , le mesures supplémentaires de cascade de signalisation , la synchronie oscillatoire , le circuit neuronaux et le voies neurales ( connectome ) font partie de biomarqueurs potentiels tout comme d'autres mesures physiologiques potentielles . ce mesures appartiennent à un continuum qui s'étend du génome au phénotype clinique du tdm et de pi utiles peuvent être identifiés à de nombreux niveaux tout au long de ce continuum . en raison de la nature hautement interactive de systèmes cérébraux et en raison de la neurobiologie complexe de la dépression , le biomarqueurs le plus utiles sont probablement ceux dont la position est intermédiaire entre le génome et le phénotype clinique du tdm . l'application de découvertes allant du génotype au phénotype permettra de mieux caractériser le anomaly complex de la signalisation et de la neuroplasticité observées dans le tdm et de mieux comprendre le cause de la dépression . huntington 's disease ( hd ) major depressive disorder ( mdd ) rdoc biomarker biosignature cognitive motivational domain cordance genotype intermediate phenotype oscillation oscillatory synchrony prediction qeeg thalamocortical dysrhythmia treatment outcome
clinical predictor therapeutic response antipsychotic schizophrenia . search clinical outcome predictor schizophrenia old field psychiatry . however , despite wealth large , longitudinal study prognostic factor , clinically useful outcome predictor identified . goal future treatment either affect modifiable risk factor , use nonmodifiable factor parse patient therapeutically meaningful subgroup . clinical outcome predictor nonspecific and/or nonmodifiable . nonmodifiable predictor poor odds remission include male sex , younger age disease onset , poor premorbid adjustment , severe baseline psychopathology . modifiable risk factor poor therapeutic outcome clinician act upon include longer duration untreated illness , nonadherence antipsychotic , comorbidities ( especially substance-use disorder ) , lack early antipsychotic response , lack improvement non-clozapine antipsychotic , predicting clozapine response . hoped limited capacity prediction improve pathophysiological understanding increase and/or new treatment specific aspect schizophrenia become available . la búsqueda de predictores de resultado clínico en la esquizofrenia e tan antigua como la psíquiatría . sin embargo , pesar de una gran cantídad de estudios longitudinales sobre los factores pronóstico , solo se han identificado unos pocos predíctores de resultado con utilidad clínica . el objetivo de la terapias futuro e influir sobre los factores de riesgo modíficables , bien emplear los factores inmodíficables para analizar los pacientes en subgrupos terapéuticamente signíficativos . la mayor parte de los predictores de resultado clínico son inespecíficos ylo inmodíficables . cuando hay una baja probabílidad de remisión los predictores inmodíficables incluyen al sexo masculíno , la menor edad de aparición de la enfermedad , un pobre ajuste premórbido una grave psicopatología basal . cuando hay pobres resultados terapéuticos los factores de riesgo modíficables sobre los cuales pueden actuar los clínicos incluyen la mayor duración de la enfermedad sín tratamiento , la falta de adherencía los antipsicóticos , la comorbilidad ( especialmente el abuso de sustancias ) , la falta de respuesta ínicial los antipsicóticos la ausencia de mejoría con antipsicóticos distintos de la clozapina , lo que puede predecír una respuesta esta última . se espera que esta capacidad límitada de predíccíón aumente en la medída que sea mayor la comprensión fisiopatológica ylo se disponga de nuevos tratamientos para aspectos específicos de la esquizofrenia . la recherche de facteurs de prédiction de résultats cliniques dans la schizophrénie est aussi ancienne que la psychiatrie elle-meme . néanmoins , malgré de nombreuses grandes études longitudinales sur le facteurs pronostiques , très peu de ce facteurs utiles cliniquement ont été identifiés . le d'un traitement futur est soit de changer le facteurs de risque modifiables ou d'utiliser de facteurs non modifiables pour regrouper le patient dans de sous-groupes déterminants sur le plan thérapeutique . la plupart de facteurs de prédiction de résultats cliniques sont non spécifiques et/ou non modifiables . le sexe masculin , un plus jeune âge au début de la maladie , un mauvais ajustement prémorbide et une pathologie psychiatrique sévère dès le début font partie de facteurs de prédiction non modifiables pour de chance de rémission médiocres . une durée plus longue de maladie non traitée , une absence d'observance de antipsychotiques , de comorbidités ( surtout l'usage de substance illicites ) , une absence de réponse précoce aux antipsychotiques et l'absence d'amélioration avec le antipsychotiques non-clozapiniques prédisant la réponse à la clozapine font partie de facteurs de risque modifiables de résultats thérapeutiques médiocres sur lesquels le médecins peuvent agir . il faut espérer que cette faible capacité prédictive s'améliorera avec une meilleure compréhension physiopathologique et/ou le développement de traitements visant de aspect spécifiques de la schizophrénie . association marker predictor psychosis remission response schizophrenia
neuroimaging biomarkers predict treatment response schizophrenia : end 30 year solitude ? study used structural magnetic resonance imaging ( mri ) suggest individual psychosis brain alteration , particularly frontal temporal cortex , white matter tract connect . furthermore , study suggest brain alteration may particularly prominent , already illness onset , individual likely poorer outcome ( eg , higher number hospital admission , poorer symptom remission , level functioning , response first treatment antipsychotic drug ) . fact , even present , brain alteration subtle distributed nature , limited , , utility mri clinical management disorder . recently , mri approach , machine learning , suggested neuroanatomical biomarkers used direct clinical benefit . example , using support vector machine , mri data obtained illness onset used predict , significant accuracy , whether specific individual likely experience remission symptom later course illness . taken together , evidence suggests validated , strong neuroanatomical marker could used inform tailored intervention strategy single individual , also allow patient stratification clinical trial new treatment . los estudios que han empleado imágenes de resonancia magnética estructural ( irm ) sugieren que los sujetos con psicosis tienen alteraciones cerebrates , especialmente en la cortezas frontal temporal , en los tractos de sustancia blanca que la conecta . además , dichos estudios sugieren que la alteraciones cerebrales pueden ser muy importantes , ya al inicio de la enfermedad , en aquellos individuos con más probabilidades de tener peor pronóstico ( por ejemplo , mayor número de hospitalizaciones , peor remisión sintomática , menor nivel de funcionamiento peor respuesta al primer tratamiento con antipsicóticos ) . de hecho , cuando estas alteraciones cerebrales están presentes , ellas son leves se distribuyen en cualquier parte , por lo que hasta la fecha la utilidad de la irm e limitada en el manejo clínico de estos trastornos . recientemente los planteamientos de la irm , partir de la técnicas aprendízaje máquina , han sugerido que estos biomarcadores neuroanatómicos pueden ser empleados con beneficíos clínicos directos . por ejemplo , empleando la técnicas de máquinas soporte de vectores para regresión , los datos obtenidos con irm al comienzo de la enfermedad han sido útiles para predetir , con precisión significativa , si un sujeto determinado puede experimentar más adelante una remisión sintomática durante el curso de la enfermedad . en su conjunto esta evidencia sugiere que los marcadores bien establecidos validados podrían emplearse solo para informar sobre estrategias de intervención la medida en un paciente individual , sino también para asignar la estratificación de pacientes en ensayos clínicos de nuevos tratamientos . selon le études de la structure cérébrale avec l'imagerie par résonance magnétique ( irm ) , le sujets psychotiques présentent de modification , particulièrement dans le cortex frontal et pariétal , et dans le faisceaux de substance blanche qui le relient . au début de la maladie , ce modification seraient prédominates chez le sujets plus susceptibles d'évoluer défavorablement ( par exemple , un plus grand nombre d'hospitalisations , une moins bonne rémission de symptômes , un niveau de fonctionnement et une réponse moins bons au premier traitement par antipsychotiques ) . le fait que ce modification cérébrales , même lorsqu'elles sont présentes , sont discrètes et de nature diffuse limité jusqu ' à présent l'utilité de l'irm dans la prise en charge clinique de ce malady . plus récemment , de technique d'irm comme celles fondées sur un auto-apprentissage par la machine , ont suggéré que ce biomarqueurs neuro-anatomiques peuvent être utilisés en vue de bénéfices cliniques . par exemple , à l'aide d'une machine à vecteurs de support , le données irm obtenues au début de la maladie ont permis de prédire , avec une précision significative , chez un patient donné , la probabilité d'une rémission plus ou moins tardive de symptômes au cours de l'évolution de la maladie . l'ensemble de ce données suggèrent que de marqueurs neuro-anatomiques validés seraient utiles non seulement pour individualiser le traitement chez un patient donné , mais aussi pour stratifier le patient dans de groupes lors de études cliniques de nouveaux traitements . first-episode schizophrenia magnetic resonance imaging psychosis
neuroimaging-based biomarkers treatment selection major depressive disorder . use neuroimaging approach identify likely treatment outcome patient major depressive disorder developing rapidly . emerging work suggests resting state pretreatment metabolic activity fronto-insular cortex may distinguish patient likely respond psychotherapy medication may function treatment-selection biomarker . contrast , high metabolic activity subgenual anterior cingulate cortex may predictive poor outcome medication psychotherapy , suggesting nonstandard treatment may pursued earlier treatment course . although finding require replication clinical adoption , provide preliminary support concept brain state measured applied selection specific treatment likely beneficial individual patient . está en pleno desarrollo el empleo de técnicas de neuroimágenes para identificar la probabilidades del resultado del tratamiento en pacientes con trastorno depresivo mayor , hay trabajos recientes que sugieren que la actividad metabólica en estado de reposo en la corteza fronto-insular pretratamiento puede distinguir entre pacientes con probabilidad de responder psicoterapia medicación , puede funcionar como un biomarcador para la selección del tratamiento . la inversa , la alta actividad metabólica en la corteza angulada anterior subgenual puede predecir un pobre resultado tanto para los fármacos como para la psicoterapia , lo que sugiere que los tratamientos habituales se podrían emplear más precozmente , aunque estos hallazgos requieren ser replicados ante de incorporarse en la clínica , ellos aportan un soporte preliminar para el concepto que se refiere que los estados cerebrales pueden ser medidos empleados en la selección de un tratamiento específico que tenga la mayor probabilidad de beneficiar un paciente individual . l'utilisation de technique de neuro-imagerie pour identifier le résultats thérapeutiques chez de patient atteints de trouble dépressif majeur , se développe rapidement . d'après de travaux récents , l'activité métabolique de repos avant traitement dans le cortex fronto-insulaire pourrait différencier le patient susceptibles de répondre à une psychothérapie ou un médicament et pourrait représenter un biomarqueur du choix thérapeutique . au contraire , une activité métabolique élevée dans le cortex angulaire antérieur ventral pourrait prédire de mauvais résultats , à la fois pour un traitement psychothérapeutique ou médicamenteux , indiquant de prévoir plus tôt dans le traitement la mise en place de mesures thérapeutiques non usuelles . ce résultats demandent à être répétés et validés avant d'être adoptés en clinique , mais il suggèrent le concept que de états cérébraux sont mesurables et peuvent être appliqués à la sélection d'un traitement spécifique plus à même de bénéficier à un patient donné . antidepressive agent biological marker depression effect modifier individualized medicine magnetic resonance imaging patient outcome assessment positron-emission tomography psychotherapy
prescription practice treatment first-episode schizophrenia spectrum disorder : data national raise-etp study . treatment guideline suggest distinctive medication strategy first-episode multiepisode patient schizophrenia . ass extent community clinician adjust usual treatment regimen first-episode patient , author examined prescription pattern factor associated prescription choice national cohort early-phase patient . prescription data study entry obtained 404 participant recovery initial schizophrenia episode project 's early treatment program ( raise-etp ) , nationwide multisite effectiveness study patient first-episode schizophrenia spectrum disorder . treatment antipsychotic exceed 6 month study entry . author identified 159 patient ( 39.4 % sample ) might benefit change psychotropic prescription . , 8.8 % received prescription recommended antipsychotic higher recommended dosage ; 32.1 % received prescription olanzapine ( often high dosage ) , 23.3 % one antipsychotic , 36.5 % antipsychotic also antidepressant without clear indication , 10.1 % psychotropic medication without antipsychotic , 1.2 % stimulant . multivariate analysis showed evidence sex , age , insurance status effect prescription practice . racial ethnic effect consistent effect reported previous study multiepisode patient found univariate analysis . despite regional variation prescription practice , region consistently different practice others . diagnosis limited inconsistent effect . besides prescriber education , policy maker may need consider patient factor also service delivery factor effort improve prescription practice first-episode schizophrenia patient .
reduction patient-reported antidepressant side effect , type collaborative care . antidepressant effective treating depression , collaborative care increase initiation adherence antidepressant . side effect antidepressant common adversely affect quality life . care manager address antidepressant side effect directly , impact collaborative care adverse effect unknown . secondary data analysis tested hypothesis patient-reported antidepressant side effect lower depressed patient receiving high-intensity , telemedicine-based collaborative care ( tbcc ) patient receiving low-intensity , practice-based collaborative care ( pbcc ) . analysis used data 190 patient enrolled pragmatic , multisite , comparative-effectiveness trial 2007 2009 followed 18 month . patient female ( 83 % ) caucasian ( 80 % ) . mean age 50 . patient randomly assigned pbcc received 12 month evidence-based care on-site primary care provider nurse care manager . patient tbcc received evidence-based care on-site primary care provider supported nurse care manager available site telephone , well telepharmacist , telepsychologist , telepsychiatrist . telephone interview completed baseline , six , 12 , 18 month included assessment sociodemographic characteristic , belief antidepressant treatment , depression severity , psychiatric comorbidity , medication , adherence , side effect . control baseline case mix time-variant medication characteristic , tbcc group reported significantly fewer side effect six 12 month ( p=.008 .002 , respectively ) . number antidepressant prescribed increased risk side effect ( p=.02 ) . patient tbcc group reported fewer antidepressant-related side effect , may contributed improved quality life .
olanzapine/fluoxetine combination child adolescent bipolar depression : randomized , double-blind , placebo-controlled trial . ass efficacy safety olanzapine/fluoxetine combination ( ofc ) acute treatment bipolar depression child adolescent . patient 10 17 year age bipolar disorder ( bp-i ) , depressed episode , baseline child 's depression rating scale-revised ( cdrs-r ) total score ≥40 , young mania rating scale ( ymrs ) total score ≤15 , ymrs-item 1 ≤2 randomized ofc ( 6/25-12/50 mg/day olanzapine/fluoxetine ; n = 170 ) placebo ( n = 85 ) 8 week double-blind treatment . primary efficacy measure mean change cdrs-r using mixed-model repeated-measures methodology . baseline-to-week-8 least-squares mean change cdrs-r total score greater ofc-treated patient placebo-treated patient ( -28.4 versus -23.4 , p = .003 ; effect size = .46 ) , between-group difference statistically significant week 1 ( p = .02 ) subsequent visit ( p < .01 ) . rate time response remission statistically significantly greater ofc- placebo-treated patient . frequent treatment-emergent adverse event ofc group weight gain , increased appetite , somnolence . mean weight gain patient 's endpoint significantly greater ofc- placebo-treated patient ( 4.4 kg versus 0.5 kg , p < .001 ) . treatment-emergent hyperlipidemia common among ofc-treated patient . abnormal increase hepatic analytes , prolactin , corrected qt interval ( qtc ) also common common generally clinically significant . study , ofc superior placebo , approved u food drug administration ( fda ) acute treatment bipolar depression patient 10 17 year age . benefit weighed risk adverse event , particularly weight gain hyperlipidemia . clinical trial registration information-a study assessing treatment patient age 10-17 bipolar depression ; http : //clinicaltrials.gov ; nct00844857 . bipolar depression olanzapine fluoxetine combination
[ new prospect antipsychotic treatment - role kynurenine pathway ] . mechanism action antipsychotic drug mainly associated change dopaminergic system . application antipsychotic agent simultaneously produce change concentration metabolite ( e.g . kynurenic acid - kyna , 3-hydroxykynurenine - 3-ohkyn , kynurenine - kyn ) kynurenine pathway , pathway engaged glutamatergic transmission . increase kyna level certain area central nervous system result inhibition glutamatergic transmission . pharmacologically induced elevation kyna level produce effect similar observed administering ketamine phencyclidine ( noncompetitive nmda receptor antagonist ) , concerning increased activity mesolimbic dopamine neuron , well reduction dopamine release prefrontal cortex . recent research result confirm predictive value change concentration kynurenine pathway metabolite assessment effectiveness antipsychotic treatment . significant relationship found 1 ) schizophrenia reduction psychopathological symptom variation 3-ohkyn level well change kyna/3-ohkyn kyn/kyna ratio , 2 ) mania varying tryptophan concentration reduction manic symptom achieved antipsychotic treatment . research well presented possibility kynurenine pathway modification , raising high hope future application target point action novel antipsychotic agent . 3-hydroxykynurenine antipsychotic kynurenic acid
[ tardive dyskinesia patient schizophrenia treated olanzapine - result 20-month , prospective , open study naturalistic condition ] . objective study ass prevalence incidence tardive dyskinesia patient treated olanzapine follow-up period 20 month . prospective , observational , non-interventional study naturalistic condition , without control group . evaluation severity presence tardive dyskinesia performed abnormal involuntary movement scale research criterion schooler kane . study included 573 patient ( woman 43,3 % ) diagnosis schizophrenia ( icd-10 ) , mean age 41.8 ( ± 12 ) year . mean dose olanzapine 15.9 ( ± 4.2 ) mg . prevalence tardive dyskinesia 16.4 % . cumulative incidence assessed group 479 patient 6.47 % . annual incidence 3.9 % . increased risk tardive dyskinesia observed smoker - rr 1.99 ( ci 0.88-4.49 ) , taking higher dos olanzapine 1.57 ( ci 0.91-2.7 ) used polytherapy : 3.55 ( ci 1.43-8.82 ) . case polytherapy multidimensional analysis confirmed factor significant influence risk tardive dyskinesia ( p=0.006 ) . study demonstrated high ( 16,4 % ) prevalence tardive dyskinesia , annual incidence ( 3,9 % ) comparable result meta-analysis corell et al . case olanzapine monotherapy annual incidence lower ( 1.96 % ) use antipsychotic polytherapy tripled risk tardive dyskinesia . olanzapine schizophrenia tardive dyskinesia
[ staging unipolar affective illness ] . article , concept staging unipolar affective illness ( recurrent depression ) presented . respective subchapters , three important aspect issue discussed : 1 ) staging unipolar affective illness ; 2 ) staging treatment-resistant depression ; 3 ) conversion unipolar bipolar affective illness . evidence called neuroprogression illness , accumulated recent year , allowed classification staging based concept allostasis allostatic load . course illness , change neuroendocrine system ( mainly hypothalamic pituitary-adrenal ( hpa ) axis ) , immunological system , mechanism oxidative stress , neurotransmitter , neurotrophic factor well structural functional change brain occur . paper 2007 , fava tossani elaborated concept staging unipolar affective illness presenting continuum model five consecutive stage specific clinical feature . present paper , concept treatment-resistant depression staging treatment resistance presented context several model . important determinant treatment-resistant depression called subthreshold bipolarity connected worse efficacy antidepressant drug . course illness , possibility changing diagnosis recurrent depression bipolar affective illness . study issue show frequency diagnostic conversion 1,5 % depressed patient per year . staging treatment-resistant depression unipolar affective illness
[ cognitive dysfunction depression - underestimated symptom new dimension ? ] . cognitive deficit constitute integral part clinical picture depression , often enough attention paid deficit , mainly presumption secondary typical depressive symptom . considered cognitive impairment one main cause depressive patient ' poor functioning . cognitive deficit observed already first depressive episode . may correlate severity depression , patient 's age level education . may persist regardless improvement depression treatment . cognitive deficit depression divided `` cold '' related emotion , `` hot '' - related emotion . `` cold '' deficit supposed respond antidepressant seem persist even clinical remission . vortioxetine novel antidepressant unique mechanism action : act serotonine reuptake inhibition , work also 5ht ( 1a ) agonist , well partial agonist 5ht ( 1b ) receptor antagonist 5ht ( 1d ) , 5ht ( 3 ) 5ht ( 7 ) receptor . preclinical study vortioxetine showed normalization serotoninergic , noradrenergic , dopaminergic transmission , additionally gaba-ergic glutaminergic effect . antidepressive property , proved efficacious various type depression ( severe , depression anxiety , depression elderly ) ; also proved efficacious patient respond sufficiently ssri snris treatment . vortioxetine also beneficial cognitive function depressed patient . cognitive deficit depression vortioxetine
paliperidone palmitate refractory clozapine-resistant schizophrenia . report two case refractory schizophrenia two case clozapine-resistant schizophrenia successful treated paliperidone palmitate . author ' knowledge , first report successful use paliperidone palmitate patient .
[ effect magnesium , acetylsalicilic acid emoxypine aggregation platelet ] . thrombin-induced platelet aggregation studied absence presence magnesium sulfate , acetylsalicylic acid emoxypine . found preparation studied able separately decrease platelet aggregation . contrast , joint action able affect aggregation platelet . data obtained used choose treatment strategy patient ischemic stroke .
therapeutic effect aripiprazole chronic schizophrenia accompanied anti-inflammatory activity . weight gain metabolic abnormality occur chronic schizophrenia patient treated atypical antipsychotic . purpose study evaluate change serum level c-reactive protein ( crp ) , insulin cytokine ( il-6 , tnf-α , il-1β , ifn-γ , stnf-r1 , il-12 , il-23 , il-1ra , tgf-β1 , il-4 , il-10 ) switching aripiprazole . cytokine , hscrp insulin measurement performed patient ( n=17 ) day 0 day 28 study using standard elisa assay . psychopathological status assessed using pan . wc bmi measured calculated , respectively . observed high clinical efficacy aripiprazole linked 2.7 % weight loss . statistically significant reduction pan score body parameter ( p < 0.001 ) . 28 day detected significant reduction hscrp ( p < 0.001 ) , insulin ( p < 0.001 ) , il-1β , il-6 , tnf-α , stnf-r1 , il-12 , il-23 , il-1ra , tgf-β1 , il-4 ( p < 0.001 ) , ifn-γ ( p < 0.05 ) significant elevation il-10 ( p < 0.001 ) . significant negative correlation il-10 level pan positive , negative total score study ( p=0.022 , p=0.003 , p=0.008 , respectively ) . aripiprazole limit inflammatory process enhancing anti-inflammatory signaling . aripiprazole also reduces risk metabolic abnormality . aripiprazole crp chronic schizophrenia cytokine
[ psychotherapeutic consideration regarding medication treatment refractory case ] . aim paper consider psychotherapeutic approach refractory case psychiatric clinic . although standardized , formulated psychotherapy , i. e. , cbt ipt , limited efficacy antidepressant-resistant chronic depression , psychotherapy medication treatment may complement combination . however , first step psychotherapeutic consideration refractory depression give seeking `` specific medicine '' exist . hand , doctor give his/her patient new hope recovery stimulate motivation treatment . dialogue doctor patient , following point focused : 1 ) essential part treatment medicine patient him-/herself . 2 ) recommendation medication reduce patient 's pride . 3 ) clear medication treatment collaborative activity patient doctor . preferable topic interview extend reconsideration prescription content reconstruction daily life . may helpful patient obtain detailed advice basic lifestyle aspect , sleep , meal , daily activity .
involvement serotonergic system effect metabotropic glutamate 5 receptor antagonist novelty-suppressed feeding test . blockade metabotropic glutamate 5 ( mglu5 ) receptor reported exert antidepressant effect several animal model . previously reported ketamine mglu5 receptor antagonist exerted effect novelty-suppressed feeding ( nsf ) test , effect ketamine may mediated α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid ( ampa ) receptor-dependent increase serotonergic transmission . however , involvement serotonergic system effect mglu5 receptor antagonist nsf test well understood . therefore , examined role serotonergic system effect mglu5 receptor antagonist , 6-methyl-2- ( phenylethynyl ) pyridine hydrochloride ( mpep ) , nsf test mouse . administration mpep significantly shortened latency feed , attenuated ampa receptor antagonist , 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo [ f ] quinoxaline-7-sulfonamide ( nbqx ) . effect mpep abolished tryptophan hydroxylase inhibitor , para-chlorophenylalanine ( pcpa ) . moreover , effect mpep blocked serotonin ( 5-ht ) 2a/2c receptor antagonist , ritanserin , 5-ht1a receptor antagonist , n- { 2- [ 4- ( 2-methoxyphenyl ) -1-piperazinyl ] ethyl } -n- ( 2-pyridynyl ) cyclohexane-carboxamide ( way100635 ) . result suggest effect mglu5 receptor antagonist may mediated serotonergic system , including stimulation 5-ht2a/2c receptor , ampa receptor-independent manner nsf test . depression ketamine metabotropic glutamate 5 receptor antagonist novelty-suppressed feeding test serotonin
sigma-1 receptor : novel intracellular target neuropsychotherapeutic drug . sigma-1 receptor ligand long expected serve drug treatment human disease neurodegenerative disorder , depression , idiopathic pain , drug abuse , cancer . recent research exploring molecular function sigma-1 receptor started unveiling underlying mechanism therapeutic activity ligand . via molecular chaperone activity , sigma-1 receptor regulates protein folding/degradation , er/oxidative stress , cell survival . chaperone activity activated inhibited synthetic sigma-1 receptor ligand agonist-antagonist manner . sigma-1 receptor localized endoplasmic reticulum ( er ) membrane physically associated mitochondrion ( mam : mitochondria-associated er membrane ) . specific type neuron ( e.g. , spinal cord ) , sigma-1 receptor also clustered er membrane juxtapose postsynaptic plasma membrane . recent study indicate sigma-1 receptor , partly sake unique subcellular localization , regulate mitochondrion function involves bioenergetics free radical generation . sigma-1 receptor may thus provide intracellular drug target enables controlling er stress free radical generation pathological condition . chaperone er stress mam sigma receptor sigma-1 receptor
[ trend psychotropic medication use among child adolescent japan data national insurance claim database 2002 2010 ] . context : despite evidence increase number young patient receiving mental health treatment , psychotropic medication approved treatment child adolescent ministry health , labour welfare . little data available psychotropic medication use child adolescent japan . establish prevalence psychotropic medication multiclass psychotropic polypharmacy outpatient aged 18 year younger japan 2002 2010 . used national insurance claim database 2002-2010 survey medical care activity public health insurance japan . prevalence psychotropic prescription psychotropic polypharmacy . study dataset comprised 233,399 outpatient visit . among patient aged 6-12 year 2002-2004 2008-2010 , significant increase prevalence adhd medication ( odds ratio [ ] 1.84 ; 95 % confidence interval [ ci ] 1.33 , 2.56 ) antipsychotic ( 1.58 95 % ci 1.06 , 2.34 ) , significant decrease prevalence sedative-hypnotic ( 0.67 ; 95 % ci 0.46 , 0.99 ) . among patient aged 13-18 year , significant increase prevalence adhd medication ( 2.49 ; 95 % ci 1.34 , 4.62 ) , anti-psychotics ( 1.43 ; 95 % ci 1.20 , 1.70 ) , antidepressant ( 1.37 ; 95 % ci 1.09 , 1.72 ) . medication frequently involved used combination two psychotropic agent mood stabilizer ( 93 % ) , followed antidepressant ( 77 % ) , sedative-hypnotic ( 62 % ) , antipsychotic ( 61 % ) , adhd medication ( 17 % ) . study revealed increase use off-label antipsychotic antidepressant among child adolescent . therefore , urgent need clinical trial evaluate efficacy psychotropic medication use child adolescent , development clinical database monitor associated long-term risk benefit .
relationship internalized stigma treatment efficacy mixed neurotic spectrum depressive disorder . many psychiatric patient suffer self-stigma . one consequence internalized prejudice decreased treatment efficacy . much written effect self-stigma patient severe mental disorder . however , individual minor psychiatric disorder also suffer self-stigma . therefore necessary explore effect self-stigma treatment efficacy neurotic patient . aim study investigate relationship self-stigma , severity symptom , presence comorbidit disorder treatment outcome neurotic patient . patient treated combined psycho pharmacotherapy . level self-stigma measured internalized stigma mental illness scale . severity anxiety depressive symptom assed beck anxiety inventory , beck depressive inventory clinical global impression scale . level self-stigma significantly correlated level anxiety , depression global evalutions mental state beginnig therapy . result patient higher level self-stigmatization lower improvement combined treatmet respect perceived anxiety symptom . self-stigma seems important factor influencing efficacy combined treatment . research focused self-stigmatization done find optimal therapeutic strategy patient higher level self-stigmatization .
elevated monoamine oxidase-a distribution volume borderline personality disorder associated severity across mood symptom , suicidality , cognition . monoamine oxidase-a ( mao-a ) treatment target neurodegenerative illness mood disorder increase oxidative stress predisposition toward apoptosis . increased mao-a level prefrontal cortex ( pfc ) anterior cingulate cortex ( acc ) occur rodent model depressive behavior human study depressed mood . extreme dysphoria common borderline personality disorder ( bpd ) , especially severe , molecular underpinnings severe bpd largely unknown . hypothesized mao-a level pfc acc would highest severe bpd would correlate symptom magnitude . [ ( 11 ) c ] harmine positron emission tomography measured mao-a total distribution volume ( mao-a vt ) , index mao-a density , severe bpd subject ( n = 14 ) , moderate bpd subject ( n = 14 ) , subject major depressive episode ( mde ) ( n = 14 ) , healthy control subject ( n = 14 ) . subject female . severe bpd associated greater pfc acc mao-a vt compared moderate bpd , mde , healthy control subject ( multivariate analysis variance group effect : f6,102 = 5.6 , p < .001 ) . bpd , pfc acc mao-a vt positively correlated mood symptom ( pfc : r = .52 , p = .005 ; acc : r = .53 , p = .004 ) suicidality ( pfc : r = .40 , p = .037 ; acc : r = .38 , p = .046 ) , hippocampus mao-a vt negatively correlated verbal memory ( r = -.44 , p = .023 ) . result suggest elevated mao-a vt associated multiple indicator bpd severity , including bpd symptomatology , mood symptom , suicidality , neurocognitive impairment . borderline personality disorder harmine imaging monoamine oxidase-a positron emission tomography suicidal behavior
doctor 's view : depression long-term care resident . none
significance ecstasy use dental practice . 3,4 methylenedioxymethampetamine ( mdma ) , commonly known ecstasy , illicit drug used individual seeking mood enhancement . ecstasy 's pharmacology , systemic , oral dental manifestation presented . use drug limited particular socioeconomic class , , practicing dentist must aware intra-oral effect drug possible alteration dental treatment might become necessary . dental manifestation include bruxism , increased incidence caries , xerostomia oral ulcer .
[ acupuncture drug subcortical ischemic vascular disease complicated depression : randomized controlled trial ] . explore difference efficacy effect mechanism subcortical ischemic vascular disease ( sivd ) complicated depression acupuncture medication . sixty patient randomized-into acupuncture group medication group , 30 case one . acupuncture group , acupuncture applied baihui ( gv 20 ) , shuigou ( gv 26 ) , fengfu ( gv 16 ) , fengchi ( gb 20 ) others , day , 6 time week . treatment 4 week made one session totally 2 session required . medication group , nimodipine 30 mg , three time day fluoxetine 20 mg , day prescribed oral administration , 8 week totally . treatment , end 4th week end 8th week treatment , cerebral blood flow velocity ( cbfv ) solubility cd40 ligand ( scd40l ) determined respectively . score montreal cognitive assessment ( moca ) hamilton ' depression scale ( hamd ) evaluated two group . efficacy cognitive function depression symptom compared patient two group . result compared outcome treatment , mean blood flow velocity ( vm ) middle cerebral artery ( mca ) , anterior cerebral artery ( aca ) posterior cerebral artery ( pca ) increased significantly end 4th week treatment two group ( p < 0.05 ) . end 8th week , vm increased much significantly ( p < 0.01 ) . difference significant comparison two group ( p > 0.05 ) . compared expression treatment , scd40l reduced significantly treatment patient two group ( p < 0.01 ) , differ- ence significant two group ( p > 0.05 ) . compared treatment , moca score increased significantly treatment two group ( p < 0.01 ) , hamd score reduced sig- nificantly ( p < 0.01 ) , difference significant comparison two group ( p > 0.05 ) . total effective rate cognitive improvement 86.7 % ( 26/30 ) acupuncture group 80.0 % ( 24/30 ) medication group , difference significant comparison two group ( p > 0.05 ) . total effective rate improvement depression 93.3 % ( 21/30 ) acupuncture group 86.7 % ( 26/30 ) medication group , difference significant comparison two group ( p > 0.05 ) . acupuncture could significantly increase cbfv reduces serum scd40l expression patient sivd complicated depression , significantly improves cognitive function relief depression symptom . efficacy similar western medication . increase serum scd40l expression possibly involved occurrence development sivd . reducing scd40l expression contributes alleviation damage induced cerebral ischemia reperfusion .
psychomotor retardation elderly untreated depressed patient . psychomotor retardation ( pr ) one core feature depression according dsm v ( 1 ) , also aging cause cognitive psychomotor slowing . first study investigating pr relation cognitive functioning concomitant effect depression aging geriatric population ruling contending effect psychotropic medication . group 28 non-demented depressed elderly compared matched control group 20 healthy elderly . participant underwent test battery containing clinical depression measure , cognitive measure processing speed , executive function memory , clinical rating pr , objective computerized fine motor skill-tests . statistical analysis consisted general linear method multivariate analysis variance compare clinical , cognitive , psychomotor outcome two group . patient performed worse clinical , cognitive , pr measure . group showed effect cognitive load fine motor function influence significantly larger patient healthy elderly except initiation time . due restrictive inclusion criterion , relatively limited sample size could obtained . medication free sample , additive effect depression aging cognition pr geriatric patient found . effect independent demand effort ( varying cognitive load ) , apparently motivational slowing effect depression . cognition copying task elderly major depression medication free neuropsychological assessment psychomotor retardation
[ protein quality control psychiatric disorder -- involvement sigma-1 receptor ] . protein quality control mechanism endoplasmic reticulum referred unfolded protein response ( upr ) , failure may involved onset psychiatric disorder . showed induction sigma-1 receptor play role upr , suggested possibility mechanism impaired disorder schizophrenia . also demonstrated fluvoxamine induces expression sigma-1 receptor . therefore , potential developed drug exerts anti-er-stress effect , i. e. , protein quality control effect .
[ effect buspirone complex glycyrrhizic acid behavior mouse anxious-depressive state ] . report study effect subchronic administration 5-ht1a receptor agonist buspirone novel complex glycyrrhizic acid ( ga ) c57bl/6j mouse different stage anxious-depressive state formation , induced condition social stress . experiment agent ' administration condition stress ( beginning initial stage ) showed complex protective effect revealed prevention anxiety high level mouse communicativeness maintenance . stage anxious-depressive state completely formed , buspirone complex ga decreased mouse motor activity however complex -- le significantly . discus possible mechanism action investigated agent background change sensitivity 5-ht1a receptor , induced formation anxious-depressive state mouse experience social stress . despite different effect agent depending stage anxious-depressive state development , novel buspirone complex ga advantage buspirone .
[ effect activation blockde gaba ( ) -receptors activity nitrergic system n. accumbens ] . sprague-dawley rat mean vivo microdialysis shown intra-accumbal infusion gaba ( ) receptor antagonist bicuculline ( 20 , 60 , 120 μm ) dose-dependently increased local level extracellular citrulline ( co-product ) . increase almost completely prevented intra-accumbal infusion 7-nitroindazol ( 0.5 mm ) , neuronal synthase inhibitor . intra-accumbal infusion ofa gaba ( ) receptor agonist muscimol concentration 10 , 50 μm affect citrulline extracellular level brain area , whereas concentration 150 μm , muscimol decreased accumbal citrulline extracellular level . intra-accumbal infusion nmda ( 100 μm ) , nmda receptor agonist , increased local level extracellular citrulline , intra-accumbal muscimol infusion ( 10 , 50 , 150 μm ) dose-dependently decreased nmda-dependent citrulline rise . data obtained indicate first time n. accumbens , gaba ( ) -receptors might regulate basal nmda-evoked activity accumbal nitrergic system .
asenapine clinical practice : preliminary result naturalistic observational study . asenapine , second-generation antipsychotic , seems effective tolerable alternative treatment patient manic mixed episode . objective naturalistic observational study identify asenapine responder remitters compare responder vs. non-responders remitters vs. non-remitters , far clinical socio-demographic feature concerned . recruited patient diagnosis manic episode bipolar ( bd ) schizoaffective disorder , clinical indication asenapine treatment . patient ’ assessment performed baseline ( t0 ) , 1 week ( t1 ) 4 week ( t2 ) treatment , young mania rating scale ( ymrs ; t0 , t1 , t2 ) hamilton rating scale depression ( ham-d ; t0 , t2 ) . according ymrs score , classified patient early improver , treatment responder , treatment remitters . significant decrease found ham-d score baseline t2 , significant difference remitters non-remitters responder vs. non-responders.the ymrs score significantly improved baseline t2 , significant difference remitters non-remitters , responder non-responders . difference found responder non-responders far socio-demographic clinical variable , questionnaire baseline score concerned . remitters non-remitters showed significant difference baseline ymrs score , lower first type current episode , frequently moderate former latter . early improver comprised 51 % subject , responder comprised 91.9 % remitters comprised 59.4 % . elderly manic patient neurological impairment and/or dementia may poorer therapeutic outcome . result suggest : 1 ) decision regarding treatment discontinuation cautious patient fail early response asenapine ; 2 ) different diagnosis ( bdor schizoaffective disorder ) seem significant impact asenapine efficacy ; 3 ) remission asenapine likely happen le severe manic episode . naturalistic study larger sample required support finding .
[ treatment-resistant depression : state art part ii . treatment ] . work would give overall up-to-date vision psychopharmacological physical strategy treatment resistant depression . pubmed search done using keywords `` resistant depression treatment '' , `` electroconvulsive therapy '' , `` antidepressant '' , inclusion criterion adult sample , english , french italian language . lot psycho-pharmacological physical treatment strategy resistant depression exist ; anyway consensus indication efficacy , appears still unsatisfactory . research move towards identification specific clinical picture treatment resistant depression develop efficacious selective treatment protocol .
genetic bioinformatic study antidepressant drug therapeutic efficacy toxicity : current overview . antidepressant relief human depression reduce human depressive symptom . nevertheless , undesired clinical event , suicide emerging . 2004 , u european regulatory agency began implementing verification program ass influence suicidal behavior use antidepressant selective serotonin reuptake inhibitor ( ssri ) . increasing number reported case , several newly developed antidepressant faced withdrawal market . despite unclear cause suicide , research focusing revealing relationship efficacy toxicity antidepressant initiated china u . deal undesired clinical consequence , new initiative revolutionary idea proposed verified . hopefully , therapeutic efficacy outcome different type antidepressant treatment improved clinical trial future .
escitalopram-induced progressive cervical dystonia . none
randomized , placebo-controlled , double-blinded trial duloxetine treatment general fatigue patient chronic fatigue syndrome . ass efficacy safety duloxetine patient chronic fatigue syndrome . 12-week , randomized , double-blind study designed compare duloxetine 60-120 mg/d ( n = 30 ) placebo ( n = 30 ) efficacy safety treatment patient chronic fatigue syndrome . primary outcome measure multidimensional fatigue inventory general fatigue subscale ( range : 4-20 , higher score indicating greater fatigue ) . secondary measure remaining multidimensional fatigue inventory subscales , brief pain inventory , medical outcome study short form-36 , hospital anxiety depression scale , center disease control prevention symptom inventory , patient global impression improvement , clinical global impression severity . primary analysis efficacy continuous variable longitudinal analysis intent-to-treat sample , treatment-by-time interaction measure effect . improvement multidimensional fatigue inventory general fatigue score duloxetine group significantly greater placebo group ( p = 0.23 ; estimated difference group week 12 = -1.0 [ 95 % ci : -2.8 , 0.7 ] ) . duloxetine group significantly superior placebo group multidimensional fatigue inventory mental fatigue score , brief pain inventory average pain severity interference score , short form-36 bodily pain domain , clinical global impression severity score . duloxetine generally well tolerated . primary efficacy measure general fatigue significantly improve duloxetine compared placebo . significant improvement secondary measure mental fatigue , pain , global measure severity suggests duloxetine may efficacious chronic fatigue syndrome symptom domain , larger controlled trial needed confirm result .
characteristic caffeine intoxication-related death tokyo , japan , 2008 2013 . caffeine widely available beverage over-the-counter product ; however , large dos , lead lethal arrhythmia . study aim clarify characteristic caffeine intoxication-related death tokyo , japan . among 4754 forensic autopsy case 2008 2013 toxicological investigation performed , case blood concentration caffeine exceeded toxic level ( 15 μg/ml ) selected ( n = 22 ) . examined subject ' age , medical history , direct/underlying cause death , manner death . also assessed concurrent drug substance detection identified origin caffeine . 60 % subject age 20 49 year ( n = 14 , 63.6 % ) . sixteen case ( 72.7 % ) showed history psychiatric disease depression sleep disorder . underlying cause death case except two caffeine intoxication , manner death classified undetermined ( n = 11 ) , accidental ( n = 7 ) , suicide ( n = 2 ) , others ( n = 2 ) . toxicological analysis revealed presence ingredient common analgesics/cold remedy 12 case ( 54.5 % ) . origin caffeine identified 11 case ( 50.0 % ) ; proportion identification significantly lower among case analgesic/cold remedy ingredient detected ( 20.0 % ) . caffeine intoxication-related death mainly occurred young middle-aged person common psychiatric disease . psychiatrist take note caffeine dependence diagnosing common psychiatric symptom . half case , origin caffeine unidentified ; nevertheless , dietary source over-the-counter drug containing caffeine suspected . becomes easier obtain caffeinated product , continuous monitoring number death caffeine intoxication , addition detailed investigation caffeine 's origin , necessary .
self-treatment informal treatment depression among resident physician . awareness depression resident physician , yet limited information self-treatment informal treatment behavior depression . study sought identify prevalence moderate severe depression , self-treatment , informal treatment depression resident physician . total 704 resident university utah sent survey depression fall 2009 , response rate 36.9 % ( 260 ) . moderate severe depression present 17.7 % ( 46/260 ) resident . 1.2 % ( 3/254 ) resident prescribed antidepressant medication , 0.8 % ( 2/257 ) resident self-treated depression sample clinic . regarding informal prescribing , 5.9 % ( 15/256 ) resident received prescription antidepressant another provider without formal clinical consultation appointment , 3.1 % ( 8/254 ) resident informally prescribed antidepressant medication another resident colleague . merely 26.7 % ( 12/45 ) resident moderate severe depression score currently receiving treatment depression . moderate severe depression resident physician common undertreated . self-treatment behavior self-prescribing use clinical sample low prevalence present . similarly , informally obtaining prescription antidepressant informally prescribing antidepressant resident exist low rate .
selective serotonin reuptake inhibitor discontinuation pregnancy : risk ?
[ licit ilicit us medicine ] . drug abuse heterogeneous group xenobiotics endobiotics alter synaptic organization central nervous system transient permanent basis , often leading compulsively use . unites member confer pleasure ( hedonism ) abuser , namely action mesolimbic dopamine system . exert effect , different drug abuse act receptor neurotransmitter transporter , modeling neurotransmitter release synaptic cleft . besides acting presynaptic neuron also function neurotransmitter receptor ion channel postsynaptic neuron , thereby modifying signaling pathway . work , pharmacodynamic potential psychoactive substance typically subjected abuse portugal , reviewed . approach also possible discussion drug abuse exhibit different toxicological effect stimulant , depressant hallucinogen . particularly , potential induce dependence addition , well undergo illicit licit us , central nervous system depressant , stimulant , anticholinergic antiparkinson drug , opioids , cannabinoids hallucinogen , discussed . drogas de abuso séo um grupo heterogéneo de xenobióticos ou endobióticos que alteram organizaçéo sináptica sistemanervoso central , de modo transitório ou permanente , conduzindo frequentemente ao consumo da droga de forma compulsiva . que une o seus membros é facto de conferirem prazer ( hedonismo ) quem consome , nomeadamente por influência sistema mesolímbico da dopamina . para exercerem o seus efeitos , diferentes drogas de abuso véo atuar sobre recetores e transportadores de neurotransmissores , modelando libertaçéo destes para fenda sináptica . além de atuar em neurónios pré-sinápticos , também atuam no recetores de neurotransmissores e canais iónicos no neurónios pós-sinápticos , ocorrendo desta forma , uma modificaçéo da vias de sinalizaçéo . nesta reviséo é discutido farmacodin'mica de algumas subst'ncias psicoativas que séo alvo de consumoabusivo em portugal . com esta abordagem é também possível uma discusséo da drogas de abuso que exibem efeitos toxicológicos téo diversos como estimulantes , depressores e alucinogénios . nomeadamente é discutido potencial do ( i.e . depressores sistema nervoso central , estimulantes , antiparkinsónicos anticolinérgicos , opioides , alucinogénios e do canabinoides ) para desenvolverem adiçéo e dependência , bem como serem alvo de utilizações lícitas e ilícitas .
[ venous thromboembolism adverse effect antipsychotic treatment ] . many study , suggest association use antipsychotic ( aps ) occurrence venous thromboembolism ( vte ) . thromboembolism often related significant r'iisk disability death . despite many year investigating interrelationsbetween use aps vte , specified yet . paper aim summarize report vte risk factor patient using aps . based analyzed clinical study , meta-analyses and.data published european medicine agency , determined , main risk factor vte duration treatment patient-related factor , gender , age , body mass , physical activity . current data allow identify prothrombotic potential individual aps indicate higher risk developing vte patient treated ' newer atypical aps . due complex pathogenesis vte would benecessaryto perform large , comparative study , allowing identify precisely difference prothrombotic potential individual aps . necessary specify product lowest vte risk , would useful treatment high-risk patient . patient treated aps assessed risk ofvte , needed , appropriate prevention method ( including elimination modifiable risk factor ) implemented . moreover , patient educated scope vte prodromal symptom . patient higher vte risk diagnosed soon possible adequate treatment implemented .
[ inhaled loxapine : novel treatment agitation psychotic disorder ] . psychomotor agitation widespread clinical problem patient schizophrenia bd . highly hazardous condition , imposing significant risk psychiatric emergency , expressedby elevated ratio adverse event traumatic experience ( patient medical staff ) . available anti-agitation drug numerous disadvantage . orally administered medication ( even though preferable : patient ) take hour even-days therapeutic effect emerge . ( also risk exacerbating agitation ) . although rapid onset action ( 15-45 minute ) noteworthy merit intramuscular drug , invasive strategy far often bound patient ' anxiety , resistance , traumatic experience . need novel drug formulation ( ideally , integrating benefit injectable orally administered tranquillizing medication , 'and free disadvantage ) , therefore , clearly grasped . development of.inhaled loxapine exemplifies attempt overcome above-delineated obstacle . suggested available research base , inhaled loxapine seems effective anti-agitation drug treatment patient schizoplhenia bd ( onset action similar one observed intramuscular antipsychotic ) . however , formulation loxapine distinguished non-invasive route administration , accompanied markedly , low risk side effect adverse event .
[ mood stabiliser pregnancy outcome - review ] . purpose review give useful information guide clinician treating pregnant woman affected bipolar disorder . review focus mood stabilizer including lithium , sodium valproate , carbamazepine , oxcarbazepine , gabapentin , lamotrigine topiramate . data extracted medline search . data prospective , retrospective case-control study well systematic review , meta-analysis data pregnancy registry included . major congenital malformation well specific malformation reported drug . preliminary finding seem identify lamotrigine one ofthe safest antiepileptic drug used pregnancy . teratogenity risk oftopiramate still largely unknown enough study draw even preliminary conclusion . preliminary study failed report increased risk major congenital malformation among gabapentin or.oxcarbazepine exposed pregnancy . even raising le concern compared valproate , carbamazepine avoided documented teratogenity risk . valproate seems worst considering major congenital malformation , specific malformation , well detrimental effect neurodevelopment . hand , lithium might considered good option treating pregnant woman affected bipolar disorder . given limited research mood stabilizer pregnancy , clinician need careful treating child bearing age woman . clinician balance potential teratogenityrisk untreated mental illness considering individual circumstance severity illness risk relapse .
[ treatment bipolar disorder ] . bipolar disorder chronic pathology whose management must lead limit social , professional family impact well suicidal risk . treatment acute episode prophylaxis based mood stabilizer treatment whose lithium leader . chosen according background history disease . anti-depressants must used care minimize risk manic episode induction rapid cycle . prognosis solving major episode avoiding major mood episode . management residual symptom ( especially neuro-cognitive ) also major challenge prognosis justifies implementation adjuvant psychotherapeutic strategy .
hamilton depression rating subscales predict antidepressant treatment outcome early course treatment . hamilton depression rating scale ( hamd ) subscales provide economic alternative full scale ; however , ability detect onset improvement early course treatment ( ei ) yet researched . present study investigated patient major depression ( md ) whether subscales comparable option predict treatment remission early course treatment . based data 210 md patient 6-week randomised , placebo-controlled trial comparing mirtazapine ( mir ) paroxetine ( par ) , discriminative predictive validity ei ( stable ) remission treatment end evaluated seven subscales hamd17 total treatment subgroup ( mir v . par ) . receiver operating characteristic ( roc ) curve ( week 2 ) clinical global impression scale ( cgi ) ( study endpoint ) used validate 20 % ei criterion subscales . evans6 toronto7 subscale almost predictive value hamd17 ( e.g. , sensitivity stable remission evans6/toronto7 : 96/95 % vs. 96 % hamd17 ) . optimal cut-off ei predict remission 20 % subscales slightly 20 % stable remission . study sample representativeness , non-independence subscales , missing external validation criterion , lack control group . evans6 toronto7 subscales valuable alternative situation , economic aspect play larger role . sum score reduction ≥20 % definition ei seems also appropriate hamd subscales , total well antidepressant subgroup . antidepressant depression early improvement hamilton depression rating scale ( hamd ( 17 ) ) outcome prediction subscales
original mechanism antipsychotic action indole alkaloid alstonine ( picralima nitida ) . alstonine major component plant based remedy traditional psychiatrist use nigeria . alstonine indole alkaloid antipsychotic experimental profile comparable clozapine compatible alleged effect mental patient . representing desirable innovation pharmacodynamics antipsychotic medication , evidence indicates alstonine bind d2 dopamine receptor ( d2r ) differentially regulates dopamine cortical limbic area . purpose study investigate effect alstonine d2r binding specific brain region using quantitative autoradiography ( qar ) effect dopamine ( da ) uptake mouse striatal synaptosomes . effect alstonine d2r binding determined nucleus accumbens caudate-putamen using qar mouse treated alstonine dos antipsychotic effect . effect alstonine [ 3h ] da uptake assessed synaptosomes prepared striatal tissue obtained mouse treated acutely 7 day alstonine . alstonine change d2r binding density studied region . da uptake increased acute ( 7 day ) treatment alstonine . consistent alstonine behavioral profile , result indicate alstonine indirectly modulates da receptor , specifically modulating da uptake . unique mechanism da transmission modulation contributes antipsychotic-like effect alstonine compatible behavioral profile mouse alleged effect patient . result may represent innovation antipsychotic development field . alstonine antipsychotic ( 2 ) dopamine receptor dopamine uptake indole alkaloid picralima nitida schizophrenia
[ treatment antipsychotic drug-induced phlegm dampness type amenorrhea wuji powder small dose aripiprazole : clinical study ] . ass efficacy safety wuji powder ( wp ) small dose aripiprazole treatment antipsychotic drug-induced phlegm dampness type amenorrhea . seventy female schizophrenic patient antipsychotic drug-induced galactorrhea-amenorrhea syndrome ( gas ) recruited randomly assigned treatment group control group , 35 group . patient received antipsychotic drug therapy . patient treatment group additionally took wp , control group took aripiprazole ( daily dose 5 mg , daily ) . therapeutic course 4 week . prolactin level obesity index [ body weight , waist aircumstance , body mass index ( bmi ) waist-hit ratio ( whr ) ] determined treatment . efficacy evaluated . treatment course completed 95.71 % patient . total effective rate 33 patient treatment group 93.94 % ( 31/33 ) , 91.18 % ( 31/34 ) 34 patient control group . difference total effective rate two group ( p > 0.05 ) . prolactin level group treatment significantly lower baseline ( p < 0.01 ) . significant difference prolactin level two group treatment ( p > 0.05 ) . compared treatment , body weight , bmi , waist circumstance , waist-hip ratio obviously decreased treatment , showing significant difference compared control group ( p < 0.05 ) . significant difference body weight , bmi , waist circumstance , waist-hip ratio control group treatment ( p > 0.05 ) . wp aripiprazole could lower high prolactin level schizophrenic phlegm dampness type amenorrhea . showed equivalent efficacy . wp showed obvious effect reducing obesity index .
treatment-resistant patient schizophrenia . none
bupropion induced premature ejaculation . none
antidepressant effect trkb ligand depression-like behavior dendritic change mouse inflammation . brain-derived neurotrophic factor ( bdnf ) receptor , tropomyosin-related kinase b ( trkb ) , signaling represent potential therapeutic target major depressive disorder . purpose study examine whether trkb ligand show antidepressant effect inflammation-induced model depression . study , examined effect trkb agonist 7,8-dihydroxyflavone ( 7,8-dhf ) trkb antagonist ana-12 depression-like behavior morphological change mouse previously exposed lipopolysaccharide ( lp ) . protein level bdnf , phospho-trkb ( p-trkb ) , trkb brain region also examined . lp caused reduction bdnf ca3 dentate gyrus ( dg ) hippocampus prefrontal cortex ( pfc ) , whereas lp increased bdnf nucleus accumbens ( nac ) . dexamethason suppression test showed hyperactivity hypothalamic-pituitary-adrenal axis lps-treated mouse . intraperitoneal ( i.p . ) administration 7,8-dhf showed antidepressant effect lps-induced depression-like behavior , i.p . pretreatment ana-12 blocked antidepressant effect . surprisingly , ana-12 alone showed antidepressant-like effect lps-induced depression-like behavior . furthermore , bilateral infusion ana-12 nac showed antidepressant effect . moreover , lp caused reduction spine density ca3 , dg , pfc , whereas lp increased spine density nac . interestingly , 7,8-dhf significantly attenuated lps-induced reduction p-trkb spine density ca3 , dg , pfc , whereas ana-12 significantly attenuated lps-induced increase p-trkb spine density nac . result suggest lps-induced inflammation may cause depression-like behavior altering bdnf spine density ca3 , dg , pfc , nac , may involved antidepressant effect 7,8-dhf ana-12 , respectively . bdnf-trkb signaling hippocampus inflammation nucleus accumbens prefrontal cortex
impact socio-economic factor suicide rate south korea . none
persistent perceptual disturbance lithium toxicity : case report discussion . none
depersonalization/derealization disorder exposure mefloquine . none
effect remission speed improvement cognitive function depressed patient . major depressive disorder ( mdd ) present neuropsychological alteration improve treatment , might mediated clinical variable . goal study whether speed remission mdd bear relation improvement patient ' cognitive functioning successful treatment . carried clinical neuropsychological assessment 51 patient mdd . procedure underwent 24-week treatment fluoxetine , assessed battery used prior treatment . arranged three group according rapid symptom remitted . patient rapid remission presented improvement working memory , speed information processing , executive function , unlike group . rapid remitters also improved episodic memory executive function patient . antidepressant response cognitive improvement generalized linear model major depressive disorder neuropsychological assessment
